Document:

Master Sales Agreement

 Exhibit 10.33 
 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 Agreement Number: Alien_______

 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 THIS MASTER SALES AND LICENSING AGREEMENT (“Agreement”) is entered as of the 16th day of December, 2002 (“Effective Date”) by and between The Gillette Company, a Delaware corporation
with offices at the Prudential Tower Building in Boston, MA 02199 (“Buyer”), and Alien Technology Corporation, a Delaware corporation with offices at 18220 Butterfield Blvd., Morgan Hill, CA 95037 (“Alien”).

 IN CONSIDERATION OF THE MUTUAL COVENANTS AND CONDITIONS SET FORTH HEREIN, THE PARTIES AGREE AS FOLLOWS: 
  

	1.	DEFINITIONS 

 1.1 “Next Financing”
shall mean the first equity financing transaction after the date hereof pursuant to which Alien raises at least $17,000,000 from persons and/or entities other than Buyer by selling and issuing, in one or more closings, one new series of its shares
of its capital stock or instruments convertible into or exchangeable for, in one or more steps, one new series of shares of its capital stock; and “Next Financing Securities” shall mean the new series of security or securities
issued in the Next Financing. 
 1.2 “Products” means Tags and Straps as defined below. 
 1.3 “Strap” means a radio frequency identification NanoBlockTM IC integrated circuit (“IC”), compliant with
Specifications as defined below encapsulated in a plastic carrier (see Exhibit E attached hereto for the dimensions and other specifications of the carrier) that has been metalized to the pads of the IC such that the carrier may be readily attached
to an antenna; 
 1.4 “Tag” means a Strap affixed to an antenna (usually but not necessarily printed or manufactured
separately from the strap) and incorporating a self-adhesive backing. The antenna contemplated by the parties for eventual use is to be approximately one inch by three inch square (1” x 3”). The parties acknowledge that Gillette is
presently working with antennas which are approximately 4 3/8” x 2” and 3 1/2” x 3 1/2” and that there will be no additional charge associated with the use of these antenna sizes. Nonstandard antenna designs or antenna sizes
other than that contemplated by the parties may result in somewhat higher pricing (see Exhibit F for examples of standard antenna designs). 
 1.5 “Specifications” means in the case of Straps or Tags the most recently released and published version of the Auto ID Center Class 1 specification, an advanced version of which is attached hereto as Exhibit C and which
is reasonably expected by the parties to become finalized by the Auto ID Center by December 2002; provided however, that any changes in the Auto ID Center Class 1 specification may require up to one year for redesign of the NanoBlockTM IC
integrated circuit before taking full force and effect as Specifications. If and when Auto ID Center compliance 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 1 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
testing becomes available, Alien will ensure that Products provided to Buyer are tested and certified as Auto ID Center compliant. In the case of Straps see
also Exhibit E regarding mechanical specifications. 
 1.6 “Shipment Date” means the date that Product leaves Alien’s
or Alien’s subcontractor’s facility for distribution to Buyer or its designee. 
  

	2.	TERMS AND CONDITIONS FOR SUPPLY OF PRODUCTS 

 2.1
Manufacturing. Alien shall sell to Buyer, and Buyer shall purchase from Alien, the Products on the terms and conditions set forth in this Agreement. The terms and conditions of this Agreement will control all sales of Products by Alien to
Buyer, and any additional or different terms, whether oral or contained in any purchase orders, invoices or like documents will be of no effect. 
 2.2 Forecasts. On or before the first day of each calendar quarter during the term of this Agreement, Buyer shall provide to Alien a 12-month non-binding rolling forecast setting forth Buyer’s estimated supply requirements for
each Product for each month of the forecast (each, a “Forecast”). Buyer acknowledges that while the Forecasts are non-binding, the Forecasts must reflect Buyer’s good faith estimate of its requirements for Products.

 2.3 Purchase Orders. Buyer shall order Products by issuing written purchase orders that set forth, without limitation, the
Agreement Number, units of Tags and units of Straps ordered, scheduled Shipment Dates, and destination (“Purchase Orders”). Alien shall ship Products in accordance with the Purchase Orders. Purchase Orders must be placed in
accordance with the lead time restrictions in Section 2.4. 
 2.4 Lead Times. Buyer shall provide Alien with a minimum order lead
time for the delivery of Products (i.e., the time between receipt of a Purchase Order by Alien and the scheduled Shipment Date) of no less than 90 days for Straps and 120 days for Tags. In each subsequent year, the Lead Times shall be reduced by not
less than 15 days, but in no event shall a Lead Time be less than 7 days. Alien will use reasonable efforts to reduce these lead times as production volume increases and Alien gains experience with Buyer’s bill of materials (e.g.,
antennas for production volumes). So long as Buyer provides Alien with the minimum order lead time, Alien shall confirm the Shipment Date via written notice to Buyer of each Purchase Order within a reasonable time period after receipt. For
those Purchase Orders for which Buyer fails to provide the minimum lead time: (a) Alien will not be obligated to accept the Purchase Order; but (b) in the event Alien does accept the Purchase Order, Alien shall use commercially reasonable
efforts to fill the Purchase Order by the Shipment Date requested by Buyer. 
 2.5 Acceptance of Purchase Orders. Purchase Orders will
be not deemed accepted by Alien unless accepted in writing by Alien. Alien shall not unreasonably reject any Purchase Order. Alien shall advise Buyer whether Alien has accepted or rejected each Purchase Order no later than 5 business days after
receipt of the Purchase Order. Alien must accept Purchase Orders placed within the leads times provided that the cumulative quantities ordered for shipment in each calendar quarter 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 2 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
were forecasted under Section 2.2 and do not exceed the Quarterly Quantity Commitments in Exhibit D. 
 2.6 Alien Quantity Commitments. Alien commits to supply, under the terms and conditions of this Agreement and specifically upon issuance and
acceptance of a Purchase Order pursuant to this Agreement, the quantities of Product listed in Exhibit D for the calendar quarters listed (“Quarterly Quantity Commitments”). For those Purchase Orders that exceed the Quarterly
Quantity Commitments for the applicable calendar quarter: (a) Alien will not be obligated to accept the Purchase Order; but (b) in the event Alien does accept the Purchase Order, Alien shall use commercially reasonable efforts to fill the
Purchase Order. 
 2.7 Shipping. All Products must be suitably packed for shipment in Alien’s or Alien’s
subcontractor’s standard containers, marked for shipment to Buyer’s address set forth above or to an address specified in the Purchase Order, and delivered to a carrier or forwarding agent chosen by Buyer. Should Buyer fail to designate a
carrier or forwarding agent, Alien shall make the designation. Shipment will be F.O.B. Alien’s plant at Morgan Hill, CA (the “Delivery Point”), at which time risk of loss and title will pass to Buyer. All freight, insurance,
and other shipping expenses from the Delivery Point, as well as any special packing expenses requested by Buyer, will be borne by Buyer. 
 2.8 Quality Control and Assurance. Alien shall perform such quality control and quality assurance tests and procedures as are required to ensure the Products meet the Specifications or as may be mutually agreed between the parties
hereafter. Upon completion of the manufacture of each shipment lot of Products, Alien shall provide Buyer with a written report of the results of said quality control and quality assurance tests and procedures with respect to that shipment lot. It
is understood that, for all purposes, Buyer may rely on said written report of results of quality control and quality assurance tests and procedures. 
 2.9 Qualification and Certification. Within 90 days of the Effective Date of this Agreement, Alien shall submit to Buyer for Buyer’s approval, which shall not be unreasonably withheld, conditioned or
delayed, a “Product Qualification and Certification Plan” specifying the procedures, limits and responsibilities for the qualification and certification of Product designs to Specifications, including without limitation, hardware
and software compliance and compatibility, environmental extremes, storage and operating life, and revision control. Buyer agrees to review and respond to Alien’s proposed Product Qualification and Certification Plan within 30 days of
submission by Alien. If the Product Qualification and Certification Plan is initially rejected by Buyer, the parties shall cooperate in good faith to develop a mutually agreeable plan within 30 days of the rejection by Buyer. If the parties fail to
agree on a mutually acceptable Plan within the 30 day period, either party may, at its option, terminate this Agreement. It is understood and agreed that any such plan will provide for certification by Alien of compliance with the Specification and
at such time as it becomes available certification by the Auto ID Center. 
 2.10 Inspection and Acceptance. Within 90 days of the
Effective Date of this Agreement, Alien shall submit to Buyer for Buyer’s approval, which shall not be unreasonably withheld, conditioned or delayed, an “Incoming Acceptance Test Procedure” specifying the test 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 3 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
procedures, sample sizes, acceptance test limits and responsibilities for the incoming acceptance and inspection of Product, including without limitation,
functional and mechanical testing and inspection. Buyer agrees to review and respond to Alien’s proposed Incoming Acceptance Test Procedure within 30 days of submission by Alien. If the Incoming Acceptance Test Procedure is initially rejected
by Buyer, the parties shall cooperate in good faith to develop a mutually agreeable Plan within 30 days of the rejection by Buyer. If the parties fail to agree on a mutually acceptable Incoming Acceptance Test procedure within 30 days, either party
may, at its option, terminate this Agreement. Buyer may, at its sole option inspect and test all Products in accordance with the Incoming Acceptance Test Procedure, and may refuse to accept Products that do not conform materially to the acceptance
test limits for those Products at any time until 90 days after the Shipment Date. In the event that any Products are materially defective in materials or workmanship, Buyer may reject those Products by giving written notice to Alien before the
expiration of the 90-day period, and Alien shall, at its expense and option (including shipping charges), replace the defective Products and redeliver conforming Products to Buyer or if replacement is not commercially practicable as determined in
Alien’s sole discretion, Alien shall refund to Buyer the Purchase Price (as defined below) for the Products. Any Products not rejected in writing within the 90-day period are deemed accepted. 
 2.11 Deferral. Buyer may, at no charge, reschedule shipments of Products for any Purchase Order by notifying Alien not less than 30 days prior to
the scheduled delivery date(s). The reschedule date is subject to the quantity and price limitations related to the Quarterly Quantity Commitment as provided in Section 2.6 and Exhibits B and D. 
 2.12 Cancellation. Buyer may, at no charge, cancel shipments of Products for any Purchase Order by notifying Alien not less than 60 days prior to
the scheduled delivery. Alien shall endeavor to accommodate cancellations of less than ninety days notice. 
 2.13 Delay in Delivery.
Alien shall notify Buyer promptly in writing in the event that the delivery of any Products under a Purchase Order will be delayed until after the scheduled Shipment Date. In the event that Alien’s delivery of any Products is delayed by more
than 15 days after the scheduled Shipment Date, Alien shall expedite shipment of such Products at its own expense. 
 2.14 Allocation.
Notwithstanding any other provision of this Agreement, in the event that Alien’s ability to supply Products is constrained such that the scheduled Shipment Date cannot be met, for any reason, including without limitation component availability,
Alien shall deliver Products for all previously accepted Purchase Orders, but thereafter Alien may reduce the quantities of Products to be supplied to Buyer in accordance with Alien’s allocation policies. In the event such allocation is not a
result of force majeure, Alien shall, at Buyer’s request, refund the Per Unit Deposit Rebate (as defined hereinafter) related to such quantities not delivered under this Section 2.12. 
  

	3.	PRICE AND PAYMENT 

 3.1 Price. The purchase
price of the Products (“Purchase Price”) to Buyer will be as set forth in Exhibit B. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 4 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 3.2 Deposit. Fifteen (15) days prior to the reasonably expected date of the last closing
of Alien’s Next Financing, Buyer shall deposit into an interest bearing escrow account, with the interest accruing to Buyer, [***] as a deposit toward the purchase of the Quarterly Quantity Commitments (the “Deposit”). The
Deposit will be held in escrow until the date of the last closing of Alien’s Next Financing, at which time it shall be released to Alien’s account, and Alien shall deliver to Buyer a Warrant (in the form attached hereto as Exhibit J). The
number of shares that may be purchased under the Warrant shall equal [***] divided by the Warrant Exercise Price, as defined in the Warrant. $0.0133 (the “Per Unit Deposit Rebate”) of the Deposit shall be applied to the Purchase
Price of the Quarterly Quantity Commitments purchased by Buyer under this Agreement until the [***] has been exhausted. Except as expressly provided in this Agreement, including, without limitation, in Section 9.2(b) hereof, this Deposit is
nonrefundable. 
 3.3 Payment. Alien shall submit an invoice to Buyer no sooner than the Shipment Date. The invoice must state the
Purchase Price for all Products plus any freight, taxes, or other applicable costs paid by Alien to be reimbursed by Buyer. Buyer shall pay all invoices within 45 calendar days of receipt of invoice. Any payments due to Alien under this Agreement
that are not paid within 5 days of the date the payments are due shall be subject to a service charge of 1% per month, calculated on the number of days that the payment is delinquent, or, if lower, the maximum charge permitted under applicable
law. This Section 3.3 shall in no way limit any other remedies available to Alien. All payments by Buyer shall be made in U.S. Dollars. 
 3.4 Taxes. All prices described herein are exclusive of applicable excise, sales, use, and similar taxes and customs, duties, tariffs, and other import/export fees and taxes. Buyer shall reimburse Alien for all the taxes that are
properly invoiced by Alien, or Buyer shall provide Alien with a properly executed tax exemption certificate. Taxes must appear as a separate item on Alien’s invoice. 
  

	4.	EARLY CUSTOMER INCENTIVE PROGRAM 

 Upon Alien’s
receipt of the Deposit from Buyer under Section 3.2, Buyer is eligible to participate in Alien’s Early Customer Incentive Program on the terms and conditions detailed in Exhibit A. 
  

	5.	CHANGES IN PRODUCT REQUIREMENTS 

 Alien shall
request from Buyer approval of any proposed modifications it intends to make that affect the form, fit, or function of the Products, unless the change is required by law in which case Alien shall give Buyer notice as reasonably practicable. Buyer
shall respond to such request within 60 days of receipt. Approval by Buyer will not be unreasonably withheld. 
  

	6.	SUPPORT 

 6.1 Support. Alien shall provide,
at no cost to Buyer, its standard, normal customer technical support. In addition, during the term of this Agreement, Alien agrees to provide to Buyer, at no additional cost, the support activities specified in Exhibit G. Support requirements beyond
the 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 5 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
normal customer technical support and the additional support activities specified in Exhibit G shall be provided by Alien to Buyer pursuant to separate
written agreement between Alien and Buyer. 
  

	7.	WARRANTY AND DISCLAIMER 

 7.1 Warranty. Alien
warrants that the Products will be materially free from defects in materials and workmanship and will conform materially to the applicable Specifications and other technical requirements agreed upon by the parties for 1 year after delivery to the
Delivery Point. 
 7.2 Warranty Remedy. Alien shall, at its option and expense, replace any Product that is in breach of the warranty
specified in Section 7.1 (each such Product referred to herein as “Non-Complying”) subject to Buyer’s notification of Alien that the Product is Non-Complying. 
 7.3 Warranty Procedures. Upon Alien’s request, made after Buyer’s notification that any particular Product is Non-Complying, Buyer shall
ship to Alien the Non-Complying Product or make it available for inspection at Buyer’s facility. The transportation costs incurred in connection with the return and redelivery of Non-Complying Products shall be borne by Alien. 
 7.4 Exclusions. The warranties set forth in Section 7.1 will not apply to defects arising from: (i) misuse, theft, vandalism, fire,
water, or other peril; (ii) alteration of or additions to the Products performed by personnel not certified by Alien to perform such alterations and additions; (iii) operation outside of environmental specifications by any party other than
Alien; (iv) any use of the Products in a manner for which it was not designed or as not authorized under this Agreement; or (v) negligence on the part of Buyer, its employees, agents, consultants, or customers. It is understood and agreed
that Buyer’s affixing to its products the Products in the normal, expected, and reasonable manner does not constitute an alteration of or addition to the Products for purposes of this Section 7.4. 
 7.5 Limitations. These warranties are solely for the benefit of Buyer. 
 7.6 Warranty. EXCEPT FOR THE WARRANTY EXPLICITLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND,
WHETHER ORAL OR WRITTEN, WHETHER EXPRESS, IMPLIED, OR ARISING BY STATUTE, CUSTOM, COURSE OF DEALING OR TRADE USAGE, WITH RESPECT TO THE SUBJECT MATTER HEREOF, IN CONNECTION WITH THIS AGREEMENT. EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED
WARRANTIES OR CONDITIONS OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, AND SATISFACTORY QUALITY. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 6 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	8.	INTELLECTUAL PROPERTY INFRINGEMENT INDEMNITY 

 8.1
Indemnity. Alien shall defend or at its option settle any lawsuit, action, or claim against Buyer alleging that any Product, when used in accordance with the restrictions in this Agreement and in the form delivered by Alien, infringes any
existing patent (issued in the United States, European Union, Japan or any PCT country as of the Effective Date) or any copyright, trademark, or trade secret of any third party, and Alien shall pay any resulting third party damages, liabilities, and
costs (including reasonable attorneys’ fees), subject to the following: Buyer shall provide Alien with: (i) prompt written notice of the claim or action; (ii) control and authority over the defense or settlement of the claim or
action; and (iii) proper and full information and reasonable assistance to defend and/or settle the claim or action. 
 8.2
Remedy. In the event that any Product is held, or in Alien’s reasonable opinion, may be held to constitute an infringement as set forth in Section 8.1, Alien, at its option and expense, may: (i) obtain for Buyer the right to
continue to use such Product as contemplated herein; or (ii) modify such Product so that it becomes non-infringing, but without altering the form, fit, and function of the Product; or (iii) replace such Products with functionally
equivalent non-infringing Products. In such event and within a reasonably prompt time period after Alien has such actual knowledge, Alien shall provide notice to Buyer of such potential infringement. 
 8.3 Limitations. Notwithstanding the provisions of Section 10.1, Alien will have no liability for infringement claims arising from:
(i) any physical combination of Products with other products not provided by Alien or manufactured or sold by Buyer or a third party, but not covering such Products standing alone; (ii) the modification of such Products unless such
modification was made or authorized in writing by Alien, where such infringement would not have occurred but for such modifications; or (iii) compliance with Buyer’s specifications, designs, or instructions where such compliance cannot be
performed without infringement. 
 8.4 Disclaimer. THE FOREGOING STATES THE ENTIRE LIABILITY AND OBLIGATION OF ALIEN AND THE EXCLUSIVE
REMEDY OF BUYER, WITH RESPECT TO ANY ALLEGED OR ACTUAL INFRINGEMENT OF PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS, OR OTHER INTELLECTUAL PROPERTY RIGHTS BY THE PRODUCTS. THE FOREGOING IS GIVEN TO BUYER SOLELY FOR ITS BENEFIT AND IN LIEU OF, AND
ALIEN DISCLAIMS, ALL WARRANTIES OF NON-INFRINGEMENT WITH RESPECT TO THE PRODUCTS. 
  

	9.	TERM AND TERMINATION 

 9.1 Term. This
Agreement commences in effect on the Effective Date and continues in force for a period of 5 years, unless earlier terminated according to the terms of this Section 9. However, the Deposit may, under a separate written agreement, be applied to
purchases from Alien by Buyer of Products after the termination of the Agreement. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 7 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 9.2 Termination. 
 (a) For Cause. Either party may, without penalty, terminate this Agreement or cancel any Purchase Order issued under this Agreement
or portion thereof effective upon written notice to the other party if the other party materially breaches this Agreement, including without limitation by failure to pay any amounts due or breach of Sections 3.2 or 3.3, and the material breach
remains uncured, if cure is possible, for 30 days following written notice of breach by the non-breaching party. 
 (b)
Related to Next Financing. 
 (i) Buyer shall have the right, at its option and in its sole discretion, to terminate
this Agreement immediately, without penalty for said termination, and receive an immediate refund of the Deposit (if previously paid), if Alien fails to raise at least $17,000,000, on or before June 30, 2003, from persons and/or entities other
than Buyer by selling and issuing, in one or more closings, one new series of its shares of its capital stock or instruments convertible into or exchangeable for, in one or more steps, one new series of shares of its capital stock. 
 (ii) In addition, Buyer shall have the right, at its option and in its sole discretion, to terminate this Agreement immediately, without
penalty for said termination, and receive an immediate refund of the Deposit (if previously paid), if the date of the last closing of Alien’s Next Financing occurs after June 30, 2003 and more than forty-five (45) days after the date
on which Buyer makes the Deposit described in Section 3.2 hereof. 
 (iii) If Buyer elects not to terminate this
Agreement pursuant to Section 9.2(b)(i) or Section 9.2(b)(ii) above, Alien shall have the right, at its option and in its sole discretion, to terminate this Agreement, without penalty for said termination, on the date of the last closing
of Alien’s Next Financing if Buyer invests less than $1 million in the Next Financing Securities; provided, however, that this Section 9.2(b)(iii) shall terminate and be of no further force or effect if the date of the last closing
of the Next Financing occurs after September 30, 2003. Should Alien exercise its right to terminate this Agreement pursuant to this Section 9.2(b)(iii), Alien shall return any remaining unapplied Deposit amounts (if previously paid) to
Buyer on the date on which Alien elects to terminate this Agreement. 
 9.3 Effect of Termination or Expiration. 
 (a) In the event of a termination or expiration of this Agreement, the provisions of this Agreement will continue to apply to all Purchase
Orders accepted by Alien prior to the effective date of the termination or expiration. Termination or expiration of this Agreement will not release either party from making payments due to the other party under the terms of this Agreement. The
Deposit made by Buyer will survive termination of the Agreement and such deposit if not returnable upon such termination may be applied by Buyer against the purchase of products after the termination date under a separate written agreement. In
addition, the provisions of Sections 1, 7.5, 7.6, 8.4, 9.3, 10, 11, and 12 will survive the termination of this Agreement for any reason. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 8 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (b) If Buyer properly terminates this Agreement under any of Sections 2.9, 2.10, 3.2,
9.2(b)(i), 9.2(b)(ii) or 12.4, or terminates this Agreement pursuant to Section 9.2(a) because Alien (i) failed to deliver Quarterly Quantity Commitments ordered by Buyer by more than 20% per quarter for two or more consecutive
quarters, or (ii) materially breaches this Agreement , Alien shall, upon Buyer’s request, return any remaining unapplied Deposit amounts to Buyer within 10 business days of receipt of the notice of termination by the appropriate party.

  

	10.	PROPRIETARY RIGHTS 

 10.1 “Confidential
Information” means any information disclosed by one party to the other either directly or indirectly pursuant to this Agreement that is confidential or proprietary information or trades secrets. Confidential Information shall include,
without limitation, any information that is marked “Confidential,” “Proprietary,” or in some similar manner or that is clearly by its nature confidential. Confidential Information shall also include, without limitation,
Alien’s or Buyer’s orders, pricing, product information, customer and supplier information, product or material specifications, systems, methods, and sales and marketing plans provided that such information has not previously been
published or disclosed by its owner to third parties without any obligation of confidentiality. Notwithstanding the foregoing, Confidential Information shall also include the items set forth or described in Exhibit H. Each party shall treat as
confidential all Confidential Information of the other party, shall not use such Confidential Information except in connection with implementing this Agreement, and shall not disclose Confidential Information to any third party. This
Section 10.1 will not apply to any Confidential Information that is or becomes generally known and available in the public domain through no fault of the receiver. 
 10.2 Notices. All proprietary notices incorporated in, marked on, or fixed to the Products or Documentation by Alien or any other third party prior to sale by Alien to Buyer must not be removed or obliterated
by Buyer. 
 10.3 No Implied Licenses. No licenses are to be implied from any term or provision of this Agreement. 
  

	11.	GENERAL WARRANTIES AND LIMITATIONS OF LIABILITY 

 11.1 General Warranties. Each party represents and warrants that: 
 (a) it has the right to enter into this
Agreement; it is a corporation duly organized, validly existing, and in good standing under the laws of the state of its incorporation; it has the corporate power and authority for, and has by all necessary corporate action authorized, the execution
and delivery of this Agreement, and the performance of its obligations hereunder; and 
 (b) the execution, performance, and
delivery of this Agreement by it will not conflict with or violate or result in any breach of, or constitute a default under, any contract, agreement, or other obligation of it. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 9 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 11.2 Limitation of Liability. EXCEPT FOR LIABILITY ARISING UNDER SECTION 10.1
(CONFIDENTIALITY), NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME, OR COST OF PROCUREMENT OF SUBSTITUTE
PRODUCTS, SERVICES, OR TECHNOLOGY), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER THE CLAIM IS BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF
THE PARTY IS ADVISED OF THE POSSIBILITY OF THE DAMAGES. THESE LIMITATIONS WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. EXCEPT FOR LIABILITY ARISING UNDER SECTION 3 (PAYMENT) OR SECTION 10.1 (CONFIDENTIALITY),
NEITHER PARTY’S AGGREGATE LIABILITY TO THE OTHER WITH RESPECT TO ANY AND ALL CLAIMS ARISING OUT OF OR RELATED TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING LIABILITY FOR THIRD PARTY CLAIMS ARISING UNDER SECTION 8, WILL EXCEED THE AMOUNTS
(INCLUDING UNAPPLIED DEPOSIT AMOUNTS) ACTUALLY RECEIVED BY ALIEN UNDER THIS AGREEMENT. 
  

	12.	MISCELLANEOUS 

 12.1 Nonassignment/Binding
Agreement. Except in the case of a transfer of all or substantially all of the assets of either party, neither this Agreement nor any rights under this Agreement may be assigned or otherwise transferred by either party, in whole or in part,
without the prior written consent of the other party, which consent it shall not unreasonably withhold, condition or delay. Subject to the foregoing, this Agreement will be binding upon and will inure to the benefit of the parties and their
respective successors and assigns. Buyer acknowledges and agrees that Alien may, in its sole option, use subcontractors to meet its obligations under this Agreement. In such event, Alien shall remain responsible for meeting all its obligations under
this Agreement. 
 12.2 Independent Contractors. The relationship of the parties under this Agreement is that of independent
contractors. Neither party will be deemed to be an employee, agent, partner, or legal representative of the other for any purpose, and neither will have any right, power, or authority to create any obligation or responsibility or make any
representation on behalf of the other. 
 12.3 Notices. Any notice required or permitted under the terms of this Agreement or required
by law must be in writing and must be (a) delivered in person, (b) sent by first class registered mail, or air mail, as appropriate, or (c) sent by overnight air courier, in each case properly posted and fully prepaid to the
appropriate address set forth in the preamble to this Agreement. Either party may change its address for notice by notice to the other party given in accordance with this Section. Notices will be considered to have been given at the time of actual
delivery in person, 3 business days after deposit in the mail as set forth above, or 1 day after delivery to an overnight air courier service. 
 12.4 Force Majeure. Neither Party shall be deemed in default hereunder, nor shall it hold the other Party responsible for any cessation, interruption or delay in the performance of its obligations hereunder if such cessation,
interruption or delay is caused, in whole or in part, by 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 10 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
events, occurrences, or causes beyond the control of such party including without limitation, acts of God, strikes, lockouts, boycott, riots, acts of war or
terrorism, power outages, earthquakes, fires, floods, and explosions, provided that the party relying on this Section (i) shall have given the other party written notice thereof promptly and, in any event, within ten (10) days of discovery
thereof and (ii) shall take all steps reasonably necessary under the circumstances to mitigate the effects of the force majeure event upon which such notice is based; provided further that in the event a force majeure event affects a
party’s performance for a period in excess of thirty (30) days in the aggregate, the other party may immediately terminate this Agreement. The inability to meet financial obligations hereunder is expressly excluded from this
Section 12.4. 
 12.5 Waiver. Any waiver of the provisions of this Agreement or of a party’s rights or remedies under this
Agreement must be in writing to be effective. Failure, neglect, or delay by a party to enforce the provisions of this Agreement or its rights or remedies at any time, will not be construed as a waiver of such party’s rights under this Agreement
and will not in any way affect the validity of the whole or any part of this Agreement or prejudice such party’s right to take subsequent action. No exercise or enforcement by either party of any right or remedy under this Agreement will
preclude the enforcement by such party of any other right or remedy under this Agreement or that such party is entitled by law to enforce. 
 12.6 Severability. If any term, condition, or provision in this Agreement is found to be invalid, unlawful, or unenforceable to any extent, the parties shall endeavor in good faith to agree to amendments that will preserve, as far as
possible, the intentions expressed in this Agreement. If the parties fail to agree on such an amendment, the invalid term, condition, or provision will be severed from the remaining terms, conditions, and provisions, which will continue to be valid
and enforceable to the fullest extent permitted by law. 
 12.7 Integration. This Agreement (including the Exhibits) contains the
entire agreement of the parties with respect to the subject matter hereof and supersedes all previous communications, representations, understandings, and agreements, whether oral or written, between the parties with respect to said subject matter.
No terms, provisions, or conditions of any Purchase Order, acknowledgement, or other business form that either party may use in connection with the transactions contemplated by this Agreement will have any effect on the rights, duties, or
obligations of the parties under, or otherwise modify, this Agreement, regardless of any failure of a receiving party to object to such terms, provisions, or conditions. This Agreement may not be amended, except by a writing signed by both parties.

 12.8 Confidentiality and Press Release. Neither party shall comment publicly on this Agreement or its contents or make any oral or
written public statements about the terms and conditions of this Agreement or disclose any terms of this Agreement to any third party without the consent of the other party, except as required by securities or other applicable laws or to prospective
and other investors or such party’s accountants, attorneys, and other professional advisors, provided that such advisors are acting under a duty of Confidentiality. Notwithstanding the above, the parties shall issue a mutually acceptable press
release no later than 15 days after the Effective Date. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 11 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 12.9 Counterparts. This Agreement may be executed in counterparts, each of which so executed
will be deemed to be an original and such counterparts together will constitute one and the same agreement. 
 12.10 Governing Law.
This Agreement will be interpreted and construed in accordance with the laws of the State of Massachusetts and the United States of America, without regard to conflict of law principles. The parties specifically disclaim the U.N. Convention on
Contracts for the International Sale of Goods. All disputes arising out of this Agreement will be subject to the exclusive jurisdiction of the state and federal courts located in Suffolk County, Massachusetts, and each party hereby consents to the
personal jurisdiction thereof. 
 12.11 Import/Export. Buyer shall not in any form export, re-export, resell, ship, or divert directly
or indirectly any Product or technical data furnished under this Agreement to any country for which the United States Government or any government agency (i) requires an export license or other government approval without first obtaining the
license or approval; or (ii) has prohibited such action. 
 12.12 No Third Party Beneficiaries. Except as expressly provided, no
provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity any rights, remedies, or other benefits under or by reason of this Agreement. 
 12.13 Exclusivity. Alien agrees not to enter into any agreement with any other party, except a party that is a member of the Board of Overseers of
the MIT Auto ID Center as of the Effective Date, which produces or markets products in a similar category to Buyer under pricing, capacity allocation, terms and conditions, that are equal to or better in the aggregate to the pricing, capacity
allocation, terms and conditions committed to Buyer under this Agreement. “Similar Category” shall mean products as defined in Exhibit I. 
 12.14 New Products. Alien Agrees to begin development of Class II Auto ID Center specification compliant straps and tags not later than March 31, 2003, provided that release and publication of a Class II
specification by the Auto ID Center is reasonably expected to occur within three (3) months of the date upon which Alien plans to begin development. 
 12.15 Headings. Headings in this Agreement are provided for convenience purposes only and shall not be used to interpret any of the terms or conditions herein. 
 12.16 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together
shall constitute one instrument. 
 (Remainder of this page is intentionally blank) 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 12 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first
above written. 
 The parties have signed below to indicate their acceptance of the terms of this Agreement. 
  

									
	ALIEN TECHNOLOGY CORPORATION	 		 	THE GILLETTE COMPANY
					
	By:	 	/S/    STAVRO E.
PRODROMO        	 		 	 By:
	 	/S/    EDWARD D.
SHIRLEY        
					
	Name:	 	Stavro E. Prodromo	 		 	 Name:
	 	Edward D. Shirley
					
	Title:	 	President & CEO	 		 	 Title:
	 	Sr. Vice President

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 13 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT A 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 EARLY CUSTOMER INCENTIVE PROGRAM 
 1. Definitions. 
  

	 	1.1.	Qualified Unit means each Strap or Tag for which full payment has been timely received by Alien from non-Alien-affiliated customers other than the U.S. Government or other
participants in the Early Customer Incentive Program (ECIP). 

 2. Purpose. The Early Customer Incentive Program
(“ECIP”) is designed to provide financial rewards to a limited group of early customers that make high volume/low cost RFID manufacture possible by placing early purchase commitments. It is agreed that the maximum number of
customers in the ECIP shall be ten (10). These customers are referred to as the “Early Customer Group” or “ECG”, but these customers are deemed to be in the ECG only for so long as they remain members in good
standing. To remain in good standing, members must have (i) an Alien sales Agreement in place with no outstanding payments materially past due and owing, (ii) met any applicable minimum purchase commitments, and (iii) not otherwise
breached the sales agreement. 
 3. Incentive Fund. Alien will create an “Incentive Fund” (“IF”) for the ECG, which
shall be distributed according to the terms and conditions in this Exhibit. 
  

	 	3.1.	Alien Contributions. Alien shall contribute to the IF: (a) [***] of [***] and [***] of the purchase price for each Qualified Unit that is a Tag sold to a purchaser that
never was an ECG member; and (b) [***] of [***] and [***] of the purchase price for each Qualified Unit that is a Strap sold to a purchaser that never was an ECG member. 

  

	 	3.2.	Distributions. On or before March 31 following each of calendar years 2006 through 2009, Alien will distribute credits to each ECG member in accordance with the
member’s participation in the ECIP. The credits may only be applied to future purchases of standard Tags and Straps from Alien pursuant to a written sales agreement. No cash payments or other consideration will be paid by Alien or any other
entity pursuant to ECIP. 

  

	 	3.3.	Participation. Buyer’s participation in the fund shall be 15% multiplied by the percentage of Buyer’s total RFID strap and tag unit requirements purchased from
Alien for the applicable calendar year. Alien agrees not to enter into an agreement with any other ECG member that provides a participation in the ECIP that is greater than or equal to 15%. For purposes of clarification, and by way of example only,
if Buyer purchases 50% of its RFID strap and tag unit requirements from Alien for calendar year 2006 and remains a member in good standing through March 31, 2007, Buyer shall, subject to all other terms and conditions of the Agreement and this
Exhibit, receive a credit for future purchases equal to 7.5% of the amount put in the IF by Alien for calendar year 2006. 

 4. Pricing.
On or before [***], ECG may purchase products at [***] for equivalent quantities and terms (subject to Alien’s pricing obligations to its RFID joint development or manufacturing 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 14 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT A 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 EARLY CUSTOMER INCENTIVE PROGRAM 
  

 
partners). It is agreed that only ECG customers will receive [***], subject to Alien’s pricing obligations to its RFID joint development or
manufacturing partners. 
 5. Term. Alien will deposit amounts into the IF relating to payments received on Qualified Units during the calendar years
2006 through 2009, inclusive. ECG members may use earned credits for purchases with a Shipment Date before December 31, 2012. No credits may be carried forward beyond 2012 and this Exhibit A shall expire on December 31, 2012. This program
will terminate immediately if it violates applicable law. Except for termination based on breach by Alien under Section 9.2(a), or expiration of the Agreement, termination of the Agreement will cause the termination of this program, including
without limitation Buyer’s ability to accrue or redeem credits. 
 6. Limited Liability. IN NO EVENT SHALL EITHER PARTY HAVE LIABILITY UNDER THIS
EXHIBIT A FOR ANY INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED AND WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE PARTY IS ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. 
 7. No Assignment or Transfer. Buyer’s
right to participate in the ECIP and IF is personal to Buyer and may not be assigned or transferred to any other entity, except by way of merger, acquisition, or operation of law. 
 8. Conflict. This program is part of and included in the Agreement and all terms and conditions of the Agreement apply to this Exhibit. However, in the event of direct conflict between the terms of the
Agreement and this Exhibit A relating to the ECIP, this Exhibit A controls. 
 9. Audit. At its sole expense, Buyer shall have the right to have
audits of the ECIP and IF performed by an independent and accredited third party accounting firm. Alien shall permit entry of Buyer’s third party auditor to its premises to perform inspections of Alien’s books and records for purposes of
conducting audits under this Agreement provided that such inspections shall be at reasonable times during normal business hours and upon reasonable notice. Audits shall not be performed more than one time per calendar year. The third party auditor
may only provide to Buyer such information specifically related to Alien’s compliance with the provisions of this ECIP Purchase Agreement. 
 10.
Allocation. Alien agrees to provide Buyer with a right of first refusal concerning any additional capacity brought on line by Alien during the term of this Agreement. For the avoidance of any doubt, Alien agrees that, to the extent that during
the term of this Agreement, Alien anticipates it will be able to produce quantities in excess of the amounts set forth in Exhibit D, Alien will immediately notify Buyer and offer such increased capacity to Buyer. Buyer agrees to respond 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 15 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT A 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 EARLY CUSTOMER INCENTIVE PROGRAM 
  

 
to Alien within 15 days as to whether or not it wishes to commit to purchase said increased capacity. In addition, other than for quantities committed under
previously accepted purchase orders or other instruments or agreements, ECG members shall receive Product allocation priority over parties that are not Alien affiliates or Alien’s joint development partners or manufacturing partners.

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 16 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT B 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 PRICES 
 The price per unit of standard Product that is within the amount of Quarterly Quantity Commitments is the lesser of: 
 For Tags: [***] or [***] (subject to Alien’s pricing obligations to its joint development partners, i.e., Buyer will not be entitled
to receive pricing [***] than that offered to Alien’s manufacturing or joint development partners or other ECG members). 
 For Straps: [***] or [***] (subject to Alien’s pricing obligations to its manufacturing or joint development partners or other ECG members). 
 The price per unit of standard Product that is in excess of the Quarterly Quantity Commitments or that is purchased with a Shipment Date after December 31, 2005 is the [***] (for similar quantities and terms).

 At any time, the [***] price for Tags or Straps that Alien provides under a voluntary written agreement to unaffiliated third parties,
other than Alien’s joint development or manufacturing partners, for equivalent volumes on similar terms and conditions shall be referred to as the [***] (for either Tags or Straps, as applicable). Any substitution of pricing under this
provision shall have no retroactive effect, nor shall this provision be construed as entitling Buyer to the return of, or credit for, any money paid by it prior to the effective date of the other agreement between Alien and the third party.

 If at any time Alien shall enter into a purchase agreement with any unaffiliated third parties, other than its RFID joint development
partners or manufacturing partners, which provides [***] pricing than that provided to Buyer, Alien shall offer Buyer the option to amend its quantities, terms or specifications to achieve [***] pricing under the same conditions. 
 If Buyer requests or requires modifications to Alien’s standard Strap or Tag (e.g., without limitation, an unusual antenna), the price per unit
shall be as mutually agreed by the parties in writing in advance of the issuance of any Purchase Order. The Quarterly Quantity Commitments apply only to Alien’s standard Products. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT C 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 SPECIFICATION 
 The Auto ID Center Technical Report, which was published on November 14, 2002 contains a total of 21 pages, including covers. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 18 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT D 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 QUANTITY COMMITMENT 
  

			
	 For Shipment Dates Within Calendar Quarter Ending
	  	Cumulative Number of Units of Standard
Product1 Alien Commits to Provide to Buyer
(Quarterly Quantity Commitment)
	 December 2002
	  	[***]
	 March 2003
	  	[***]
	 June 2003
	  	[***]
	 September 2003
	  	[***]
	 December 2003
	  	[***]
	 March 2004
	  	[***]
	 June 2004
	  	[***]
	 September 2004
	  	[***]
	 December 2004
	  	[***]
	 March 2005
	  	[***]
	 June 2005
	  	[***]
	 September 2005
	  	[***]
	 December 2005
	  	[***]

	1	Number of Product includes the combined number of units of standard Tags and Straps that Alien commits to shipping to Buyer, under the terms and conditions of the
Agreement, in a given quarter. For example, if Alien commits to supplying 100 units in a quarter, Buyer may buy 100 Tags or 100 Straps or 50 Tags and 50 Straps in that quarter, but the Quarterly Quantity Commitment does not include 75 Tags and 75
Straps shipped in that quarter. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 19 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT E 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 STRAP MECHANICAL OUTLINE 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 21 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT F 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 SAMPLE ANTENNA DESIGNS 
 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 22 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT G 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 ADDITIONAL SUPPORT 
 Alien agrees to provide the following additional support to Gillette as part of Alien’s obligations under the Agreement. Alien’s obligations in
the aggregate shall not exceed one thousand (1,000) man-hours per year, for three years. Additional support will be quoted to Gillette at Alien’s then current rates for the particular levels of employees utilized. 
 1. Alien will provide reasonable support to Gillette to help process map Gillette’s Customer Value Chain to help Gillette determine appropriate
applications for Auto-ID and the Products. 
 2. Alien will provide all necessary technical support to Gillette to help design packaging
solutions to enable Gillette to integrate Alien tags/straps into all Gillette packaging. Alien agrees to work closely with Gillette internal and external packaging personnel and vendors to accomplish this objective to the reasonable satisfaction of
Gillette. 
 3. Alien will provide all necessary technical support for test pilots and implementation of Auto-ID technology to ensure
effective tag/strap reader capability, working within ranges that are reasonably acceptable to Gillette for distance and speed. 
 4. Alien
will provide technical support as requested by Gillette to evaluate and test shelf antenna and readers that Gillette purchases from Alien. 
 5. Alien will provide Gillette’s Advanced Technology Group with information and technical support to assist Gillette with the development of “smart” products. 
  

 Page 23 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT H 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 CONFIDENTIAL INFORMATION 
 1) Alien’s additional Confidential Information: 
 a)
FSA process, equipment, and future plans related thereto 
 b) Cost structure 
 c) Suppliers of components and materials 
 d) Strap and tag assembly specifications, bills of materials, and test methods 
 e) Pro Forma Financial Plans 
 f) Capitalization structure and shareholders 
 2)
Buyer’s additional Confidential Information: 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -1- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT I 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 SIMILAR CATEGORY 
 1. Non-rechargeable alkaline and non-alkaline consumer batteries, 
 2.
Consumer human hair-wet and dry shaving products such as razors, pre and post shave preparations including shaving foams and gels, 
 3. Manual and power
toothbrushes, 
 4. Small household appliances, and 
 5. Blood
pressure meters and ear thermometers. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -1- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES AGREEMENT 
 FORM OF WARRANT 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED.

  

 WARRANT TO PURCHASE
SHARES 
 This Warrant to Purchase Shares (this “Warrant”) is issued to The Gillette Company, a Delaware corporation, by Alien
Technology Corporation, a California corporation (the “Company”), on this __ day of ______________, 200_. This Warrant is issued pursuant to that certain Alien Technology Master Sales Agreement, dated as of December __, 2002 (the
“Sales Agreement Date”), a copy of which is attached hereto as Attachment A. 
 1. Purchase of Shares. Subject to the terms
and conditions hereinafter set forth, the Holder (as defined below) is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the Holder hereof in writing), to purchase
from the Company up to the number of fully paid and nonassessable Shares (as defined below), that equals the quotient obtained by dividing (a) the Warrant Coverage Amount (as defined below) by (b) the Warrant Exercise Price (as defined
below). 
 2. Definitions. 
 (a) Change of Control. The term “Change of Control” shall mean (i) any consolidation or merger involving the Company pursuant to which the Company’s stockholders own less than fifty
percent of the voting securities of the surviving entity or (ii) the sale of all or substantially all of the assets of the Company. 
 (b) Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the closing date of a Qualified Equity Financing and ending on the expiration of this Warrant pursuant
to Section 14 hereof. 
 (c) Holder. The term “Holder” shall mean any person or entity that shall
be the registered holder of this Warrant. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 (d) Qualified Equity Financing. The term “Qualified Equity
Financing” means the first equity financing transaction after the Sales Agreement Date pursuant to which the Company raises at least $17,000,000 from persons and/or entities other than the Holder by selling and issuing, in one or more
closings, one new series of its shares of its capital stock or instruments convertible into or exchangeable for, in one or more steps, one new series of shares of its capital stock. 
 (e) Shares. The term “Shares” shall mean the class and series of stock issued to investors in a Qualified Equity
Financing. 
 (f) Warrant Coverage Amount. The term “Warrant Coverage Amount” shall mean that amount
which equals [***]. 
 (g) Warrant Exercise Price. The exercise price for the Shares shall be (i) 150 percent of
the price per share of the equity securities sold to investors in a Qualified Equity Financing if this Warrant is exercised by the last day of the 12th month following the closing of such Qualified Equity Financing or (ii) 200 percent of the price per share of the equity securities sold to investors in a Qualified Equity Financing if this
Warrant is exercised after the last day of the 12th month, but prior to the last day of the 18th month, following the closing of such Qualified Equity Financing (such price, as adjusted from time to time, is herein referred
to as the “Warrant Exercise Price”). 
 3. Method of Exercise. While this Warrant remains outstanding and exercisable
in accordance with Section 2 above, the holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by: 
 (i) the surrender of the Warrant, together with a notice of exercise to the Secretary of the Company at its principal offices; and

 (ii) the payment to the Company of an amount equal to the aggregate Warrant Exercise Price for the number of Shares being
purchased. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -2- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 4. Net Exercise. In lieu of exercising this Warrant pursuant to Section 3 above, the
Holder may elect to receive, without the payment by the Holder of any additional consideration, Shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with notice of such election, in which event the Company shall issue to the Holder a number of Shares computed using the following formula: 
  

					
	X =  	  	Y (A - B)	  	
		  	A	  	

 Where 
 X —    The number of Shares to be issued to the Holder pursuant to this net exercise. 
 Y —    The number of Shares in respect of which the net exercise election is made. 
 A —    The fair market value of one Share. 
 B —    The Warrant Exercise
Price (as adjusted to the date of such calculations). 
 For purposes of this Section 4, the fair market value of one Share as of a
particular date shall be determined as follows: (i) if traded on a securities exchange or through the Nasdaq Stock Market, the value shall be deemed to be the average of the closing prices of the Shares on such exchange over the thirty
(30) day period ending three (3) days prior to the net exercise election; (ii) if traded over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty
(30) day period ending three (3) days prior to the net exercise election; and (iii) if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Board of Directors of the
Company; provided, that, if the Warrant is being exercised upon the closing of an initial public offering of the Company, the value will be the initial “Price to Public” of one share of such Shares specified in the final prospectus with
respect to such offering. 
 5. Certificates for Shares. Upon the exercise of the purchase rights evidenced by this Warrant, one or
more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within 30 days of the delivery of the subscription notice. In case the Holder shall exercise this Warrant with respect to
less than all of the Shares that may be purchased under this Warrant, the Company shall execute a new warrant in the form of this Warrant for the balance of such Shares and deliver such new warrant to the Holder of this Warrant. 
 6. Issuance of Shares. The Company covenants that it will at all times keep available such number of authorized shares of its Shares, free from
all preemptive rights with respect thereto, which will be sufficient to permit the exercise of this Warrant for the full number of Shares specified herein. The Company covenants that the Shares, when issued pursuant to the exercise of this Warrant,
will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -3- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 7. Adjustment of Warrant Exercise Price and Number of Shares. The number of and kind of
securities purchasable upon exercise of this Warrant and the Warrant Exercise Price shall be subject to adjustment from time to time as follows: 
 (a) Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of this Warrant subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue
additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a
combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any
adjustment under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the
making of such dividend. 
 (b) Reclassification, Reorganization and Consolidation. In case of any reclassification,
capital reorganization, or change in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 7(a) above), then, as a condition of such reclassification, reorganization,
or change, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right at any time prior to the expiration of this
Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by
a holder of the same number of Shares as were purchasable by the Holder immediately prior to such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the
Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share
payable hereunder, provided the aggregate purchase price shall remain the same. 
 (c) Notice of Adjustment. When any
adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant, or in the Warrant Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Shares or other securities
or property thereafter purchasable upon exercise of this Warrant. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -4- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 (d) No Impairment. The Company and the Holder of this Warrant will not, by any
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company or the Holder of this Warrant, respectively, but will at all times in good faith assist in the carrying
out of all the provisions of this Section 7 and in the taking of all such action as may be reasonably necessary or reasonably appropriate in order to protect the rights of the Company and the Holder of this Warrant against impairment.

 8. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Warrant Exercise Price then in effect. 
 9. Representations of the Company. The Company represents that all corporate actions on the part of the Company, its officers, directors and stockholders necessary for the sale and issuance of this Warrant have
been taken. 
 10. Representations and Warranties by the Holder. The Holder represents and warrants to the Company as follows:

 (a) This Warrant is being acquired for its own account, for investment and not with a present view to resale or
distribution, except pursuant to sales registered under the Securities Act of 1933, as amended (the “Act”). Upon the exercise of this Warrant, unless this Warrant is exercised upon the closing of a public offering within the
meaning of the Act, the Holder shall, if so requested by the Company, confirm in writing, in a form reasonably satisfactory to the Company, that the Shares issuable upon exercise of this Warrant are being acquired for investment and not with a
present view toward distribution or resale. 
 (b) The Holder understands that this Warrant and the Shares have not been
registered under the Act and that they must be held by the Holder unless a subsequent disposition thereof is registered under the Act or is exempted from such registration. 
 (c) The Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks
of the purchase of this Warrant and the Shares purchasable pursuant to the terms of this Warrant and of protecting its interests in connection therewith. 
 (d) The Holder is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -5- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 (e) The Holder is an “accredited investor” as such term is defined in Rule
501 of Regulation D promulgated under the Act. 
 11. Restrictive Legend. 
 The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY AT THE PRINCIPAL EXECUTIVE
OFFICES OF THE COMPANY. 
 The Shares shall also be stamped or imprinted with any legend required by the laws of the State of California,
including any legend required by the California Department of Corporations and/or the California Corporations Code. 
 12. Transfer of
Warrants. This Warrant shall not be conveyed or transferred by the Holder, in whole or in part, without the Company’s prior written consent; provided, however, that this Warrant may be conveyed or transferred without the prior
written consent of the Company to any person that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the Holder. 
 13. Rights of Stockholders. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a shareholder with respect to the
Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions thereon, exercise preemptive rights or be notified of shareholder meetings. However, nothing in this Section 13 shall limit the right
of the Holder to be provided the notices required under this Warrant; and provided further, however, that the Company will afford to the Holder the right, upon advance notice, to meet periodically with 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -6- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 
the Company’s chief financial officer during mutually agreeable business hours to discuss the Company’s business and affairs. 
 14. Expiration of Warrant; Notice of Certain Events Terminating This Warrant. 
 This Warrant shall expire and shall no longer be exercisable upon the earlier to occur of: 
 (i) 5:00 p.m., California local time, on the last day of the 18th month following the closing of a Qualified Equity Financing; or 
 (ii) the effective date of any Change of Control, but only if the Company has provided at least twenty (20) days prior written notice of any pending Change of Control. 
 15. Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in
any event be deemed to be given upon receipt or, if earlier, (a) five days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by
hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one business day after the business day of facsimile transmission, if delivered by facsimile
transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to the Holder, at Prudential Tower Building, Boston, Massachusetts 02199 (attention: General Counsel), or such other address as the Holder may provide to
the Company in writing, and (ii) if to the Company, at the address of its principal corporate offices (attention: Chief Financial Officer). 
 16. “Market Stand-Off” Agreement. Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the effective date of a
registration statement of the Company filed under the Act, it shall not, to the extent requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant
any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration;
provided, however, that such market stand-off time period shall not exceed 180 days for the Company’s initial public offering, and 90 days for any subsequent public offerings. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -7- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 17. Successors and Assigns. The terms and provisions of this Warrant shall inure to the
benefit of, and be binding upon, the Company and the Holder and their respective successors and assigns. 
 18. Amendments and
Waivers. Any term of this Warrant may be amended and the observance of any term of this Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and
the Holder. Any waiver or amendment effected in accordance with this Section 18 shall be binding upon each holder of any Shares purchased under this Warrant at the time outstanding (including securities into which such Shares have been
converted), each future holder of all such Shares, and the Company. 
 19. Attorneys’ Fees. If any action of law or equity is
necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be entitled to its reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. 
 20. Captions. The section and subsection headings of this Warrant are inserted for convenience only and shall not constitute a part of this
Warrant in construing or interpreting any provision hereof. 
 21. Governing Law. This Warrant and all actions arising out of or in
connection with this Agreement shall be governed by and construed in accordance with the laws of the state of California, without regard to the conflicts of law provisions of the state of California or of any other state. 
 22. Rights and Obligations Survive Exercise of Warrant. Unless otherwise provided herein, the rights and obligations of the Company, of the holder
of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant. 
 [SIGNATURE PAGE FOLLOWS] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -8- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 EXHIBIT J 
 ALIEN TECHNOLOGY MASTER SALES
AGREEMENT 
 FORM OF WARRANT 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant to be executed by an officer
thereunto duly authorized. 
  

			
	ALIEN TECHNOLOGY CORPORATION
		
	 By:
	 	  
		
	 Name:
	 	  
		
	 Title:
	 	  
	
	THE GILLETTE COMPANY
		
	 By:
	 	  
		
	 Name:
	 	  
		
	 Title:
	 	  

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -9- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT A 
 NOTICE OF EXERCISE 
  

	TO:	Alien Technology Corporation 

 18220 Butterfield Blvd.

 Morgan Hill, CA 95037 
 Attention: Chief Financial Officer 
 1. The undersigned hereby elects to purchase __________ Shares of _____________ pursuant to
the terms of the attached Warrant. 
 2. Method of Exercise (Please initial the applicable blank): 
  

	 	 ̈	The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders herewith payment in full for the purchase price of the shares being purchased,
together with all applicable transfer taxes, if any. 

  

	 	 ̈	The undersigned elects to exercise the attached Warrant by means of the net exercise provisions of Section 4 of the Warrant. 

 3. Please issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified below:

 _____________________________________ 
 (Name) 
 _____________________________________ 
 _____________________________________ 
 (Address) 
 4. The undersigned hereby represents and warrants that the aforesaid Shares are being acquired for the account of the undersigned for investment and not
with a view to or for resale in connection with the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares and all representations and warranties of the undersigned set forth in
Section 10 of the attached Warrant (including Section 10 (e) thereof) are true and correct as of the date hereof. 
  

					
		 		 	_____________________________________
	 	 		 	(Signature)
			
		 		 	_____________________________________
		 		 	(Name)
			
	 _____________________________________
	 		 	_____________________________________
	 (Date)
	 		 	(Title)

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -10- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 AMENDMENT TO THE ALIEN TECHNOLOGY 
 MASTER SALES AGREEMENT 
 This Amendment (the “Amendment”) to that certain Alien
Technology Master Sales Agreement, dated as of December 16, 2002 (the “Master Sales Agreement”), by and between Alien Technology Corporation (“Alien”) and The Gillette Company (“Gillette”), is entered into and
delivered by Alien and Gillette as of June 23, 2003. 
 WHEREAS, Alien and Gillette entered into the Master Sales Agreement, pursuant to which,
among other things, Alien agreed to manufacture and sell to Gillette, and Gillette agreed to purchase from Alien, certain defined products; and 
 WHEREAS, Gillette and Alien have agreed to amend certain terms of the Master Sales Agreement pursuant to this Amendment. 
 NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: 
 1. Definitions. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings ascribed to them in the Master Sales Agreement. 
 2. Amendment to Section 3.2 of the Master Sales Agreement. Section 3.2 of the Master Sales Agreement is amended in its entirety to read as follows:

 “3.2 Deposit. On the last closing date of Alien’s Next Financing, which the parties agree shall occur on or before
July 21, 2003, (i) Buyer shall pay [***] as a deposit (the “Deposit”) toward the purchase of the Quarterly Quantity Commitments to Alien by wire transfer of immediately available funds to an account identified by Alien at least
three (3) business days prior to the last closing date of Alien’s Next Financing and (ii) Alien shall deliver to Buyer a Warrant (in the form attached hereto as Exhibit J). The number of shares that may be purchased by Buyer under the
Warrant shall equal [***] divided by the Warrant Exercise Price, as defined in the Warrant. $0.0133 (the “Per Unit Deposit Rebate”) of the Deposit shall be applied to the Purchase Price for each unit of Product that is within the Quarterly
Quantity Commitments purchased by Buyer under this Agreement until the Deposit has been exhausted. Except as expressly provided in this Agreement, including, without limitation, in Section 9.2(b) hereof, the Deposit is nonrefundable.”

 3. Amendment to Section 9.2(b) of the Master Sales Agreement. Section 9.2(b) of the Master Sales Agreement is amended in its entirety to
read as follows: 
 “(b) Related to Next Financing.  
 (i) Buyer shall have the right, at its option and in its sole discretion, to terminate this Agreement on any date from July 22, 2003
through July 31, 2003, without penalty for 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -11- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
said termination, and receive an immediate refund of the Deposit (if previously paid), if the last closing date of Alien’s Next Financing fails to occur
on or before July 21, 2003. 
 (ii) Alien shall have the right, at its option and in its sole discretion, to terminate
this Agreement, without penalty for said termination, at any time during the ten (10) consecutive day period immediately following the date of the last closing of Alien’s Next Financing if, and only if, all of the following
three conditions are met: (A) the last closing date of Alien’s Next Financing occurs after July 21, 2003, and (B) Buyer has not exercised its right to terminate this Agreement pursuant to Section 9.2(b)(i)
above and (c) Buyer has invested less than $1 million in the Next Financing Securities; provided, however, that this Section 9.2(b)(ii) shall terminate and be of no further force or effect if the date of the last closing of
the Next Financing occurs after September 30, 2003. Should Alien exercise its right to terminate this Agreement pursuant to this Section 9.2(b)(ii), Alien shall return any remaining unapplied Deposit amounts (if previously paid) to Buyer
on the date on which Alien elects to terminate this Agreement.” 
 4. Effect of Amendment on the Master Sales Agreement. Except for the
amendments to the Master Sales Agreement provided above, all other terms and conditions of the Master Sales Agreement shall remain in full force and effect. 
 [SIGNATURE PAGE FOLLOWS] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -12- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their respective officers thereunto
duly authorized. 
  

									
	ALIEN TECHNOLOGY CORPORATION	 		 	THE GILLETTE COMPANY
					
	 By
	 	/S/    STAVRO E.
PRODROMO        	 		 	 By
	 	  
					
	 Name:
	 	Stavro E. Prodromo	 		 	 Name:
	 	
					
	 Title:
	 	Chief Executive Officer	 		 	 Title:
	 	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -13-Agreement between the Registrant and Impinj, Inc.

 Exhibit 10.36 
 CONFIDENTIAL INFORMATION REQUESTED BY ALIEN TECHNOLOGY CORP. 
 FIRST AMENDMENT TO AGREEMENT

 This FIRST AMENDMENT TO AGREEMENT (the “First Amendment”) is made and effective as of September 29, 2005, by and
between Alien Technology Corporation, a Delaware corporation (“Alien”) and Impinj, Inc., a Delaware corporation (“Impinj”) under the following circumstances: 
 A. On June 10, 2005, Alien and Impinj entered into an Agreement (“Agreement”) for the supply of Gen 2 Specification compliant RFID tag
silicon integrated circuits (“Monza”); and 
 B. Alien and Impinj desire to modify the terms of the Agreement on such terms and
conditions as are set forth in this First Amendment. 
 NOW THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which hereby are expressly acknowledged, the Parties agree as follows: 
 1. Any words with an
initial capitalized letter in this Amendment not defined in this First Amendment shall have the meaning given to such words in the Agreement. Terms defined in this First Amendment that are not defined in the Agreement shall have the meaning given to
such term herein. 
 2. Without waiving rights or obligations under the Agreement, the parties acknowledge that the Product Acceptance Date
is September 29, 2005. Alien shall pay Impinj the Pre-Paid Amount not later than seven (7) days following the effective date of this First Amendment. 
 3. With respect to the Pre-Paid Amount, Impinj’s estimated NRE fees for the development of Monza-FSA, in lieu of the first two sentences of Section 6(e) of the Agreement, will be [***] split into three
categories: 
 (a) Wafer and mask charges ([***]) 
 As a consequence of (a) above, Impinj will incur expenses of approximately [***] for mask charges and to procure the preliminary 6 wafers from 2 separate engineering lots for Impinj evaluation of Monza-FSA.

 (b) Labor charges ([***]) 
 Impinj will use commercially reasonable efforts to keep Labor charges (b, above) less than [***], provided however that the Labor charges to Alien shall in no event exceed [***]. These charges will cover labor hours related to design,
layout, test engineering and evaluation of Monza-FSA. Costs above [***] for (b) above need to be mutually agreed to before being incurred by Impinj. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Delivery of six Monza-FSA wafers to Alien ([***]) 
 Per section 3(c) above, Impinj will make available 6 additional wafers of Monza-FSA to Alien for the purposes of determining suitability for the FSA
process. 
 All other Monza-FSA wafers purchased by Alien will not be considered as a portion of the NRE fees (defined in sections (5.(a).iii.1) and
(6.e) of the Agreement. 
 Impinj will meet the following schedule: 
  

					
	  	  	 Milestone
	  	 Date

	 (i)
	  	 Start Monza 1A layout for FSA
	  	 [***] (target date).

	 (ii)
	  	 Tapeout of Monza-FSA
	  	 [***] (target date).

	 (iii)
	  	 Engineering silicon samples
	  	 [***] (target date).

	 (iv)
	  	 Production
	  	 UponAlien acceptance & release, but not later than [***].

 All of the provisions of the Agreement not specifically amended as set forth in this First
Amendment remain in full force and effect. Except as expressly set forth herein, nothing in this First Amendment shall be construed to constitute a waiver by Impinj or Alien of any provision of the Agreement. This First Amendment along with the
Agreement (including the exhibits thereto) contain the entire agreement between the parties with respect to the subject matter of this First Amendment and the Agreement and supersede all previous communications, representations, understandings and
agreements, either oral or written, between the parties with respect to said subject matter. This First Amendment may be executed in counterparts, each of which when so executed will be deemed an original and such counterparts together will
constitute one and the same agreement. 
  

									
	Alien Technology Corporation	 		 	Impinj, Inc.
					
	 By: 
	 	 /s/ John Payne
	 		 	 By: 
	 	 /s/ William T. Colleran

			
	 Print Name:  John Payne
	 		 	 Print Name:  William T. Colleran

			
	 Title:  Chief Operating Officer
	 		 	 Title:  President

  

 2 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Agreement 
 This agreement (the “Agreement”) is entered into as of June 10, 2005 (the “Effective Date”) by and between Impinj, Inc., a Delaware corporation with its principal place of business
located at 501 N. 34th Street, Suite 100, Seattle, WA 98103 (“Impinj”), and Alien Technology Corporation, a Delaware corporation with its principal place of business located at 18220 Butterfield Blvd., Morgan Hill, CA 95037
(“Alien”) (each a “party” and collectively the “parties”). 
 Recitals 

Impinj desires to sell to Alien, and Alien desires to purchase from Impinj, Impinj’s initial implementation of EPCglobal’s Gen 2
Specification compliant RFID tag silicon integrated circuit (“Monza”) and/or certain future versions of Monza, as set forth below; 
 The parties desire that Alien place an immediate order of 24 risk wafers of Monza, Alien commit to a prepayment in the amount of [***], Alien commit to a minimum purchase amount of [***] units of Product, and that Impinj perform its
obligations and deliver the deliverables required of it hereunder so that Alien may assemble RFID straps, inlay and/or label products using wafers supplied by Impinj hereunder, all as set forth below; 
 In consideration of the mutual promises contained herein, the parties agree as follows: 
 Agreement 
  

	1.	Definitions. The following terms shall have the following meanings: 

 “Confidential Information” means any information disclosed by one party to the other in connection with the performance of this Agreement, including Intellectual Property and other information that
relates to the disclosing party’s products, designs, business plans, business opportunities, finances, research, development, know-how, personnel, or third-party confidential information disclosed to the receiving party by the disclosing party
in any form whatsoever (including, but limited to, disclosure made in writing, orally or in the form of samples, models, computer programs or otherwise), and the terms and conditions of this Agreement, provided that such information is at the time
of disclosure either designated as “confidential”, “proprietary,” or similar legend or reasonably should be known to the receiving party to be confidential. Confidential Information does and will not include material that:
(i) is now or subsequently becomes generally available to the public or is disclosed to third parties without restriction on its use or disclosure; (ii) the receiving party had rightfully in its possession prior to disclosure by the
disclosing party; (iii) is developed independently by or for the receiving party without the use of any Confidential Information of the disclosing party; (iv) the receiving party rightfully obtains without restriction from a third party
who has the right to transfer or disclose it; or (v) is disclosed with the prior written approval of the disclosing party. 
  

 3 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Assembled Parts” means a Product included as a component of an Alien strap, inlay
or finished label that is intended for shipment to Alien’s customer. 
 “EPCglobal” means EPCglobal Inc., and its
successors and assigns. 
 “Epidemic Failure” means a series of failures (i) indicating a common or systemic Product
failure related to the same or similar root cause, (ii) equal to or in excess of [***] of the total number of Assembled Parts during any rolling [***] month period; and (iii) resulting in the failure of Products to meet the Limited
Product Warranty, (iv) during the Limited Warranty Period. 
 “FSA Intellectual Property” has the meaning set forth in
Section 2(c). 
 “Gen2 Specification” means any Class 1, Generation 2 specification that is ratified by
EPCglobal’s Board of Governors. 
 “Intellectual Property” means all circuit designs, hardware description language
coding, software (including firmware), simulation models, schematics, layout topologies, cells, libraries, data, formulas, designs, software, other original works of authorship, applications, processes, products, know-how, techniques, programs,
improvements, test protocols, test structures, characterization and test results, methods and patterns, specifications and other technical information, whether or not patentable or otherwise protectable. 
 “Intellectual Property Rights” means all copyright rights, patent rights (including reissues, divisions, renewals, extensions,
provisionals, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries), trademark rights, trade secret rights, moral rights, rights of publicity, authors’ rights,
semiconductor mask work rights, contract and licensing rights, goodwill and all other intellectual property rights as may exist now and/or hereafter come into existence and all applications therefor and registrations, renewals and extensions
thereof, regardless of whether such rights arise under the law of the United States or any other state, country, jurisdiction or international treaty. 
 “KGD” shall mean the known good die on a Product wafer. For Monza and Monza-2 wafers, the number of known good die will be determined as measured by Impinj during Testing of the Product in wafer form.
For Monza-FSA, the number of known good die will be determined by Impinj via the Sample Testing Procedure. 
 “Limited Product
Warranty” shall have the meaning set forth in Section 9(a)(i). 
 “Limited Warranty Period” shall mean
one (1) year from the date that Products are received by Alien. 
 “Minimum Purchase Amount” shall have the meaning set
forth in Section 4(a). 
 “Monza” shall have the meaning set forth in the Recitals. 
  

 4 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Monza Specifications” shall have the meaning set forth in
Section 2(a)(i). 
 “Monza-2” shall have the meaning set forth in Section 2(b). 
 “Monza-2 Specifications” shall have the meaning set forth in Section 2(b). 
 “Monza-FSA” shall have the meaning set forth in Section 2(c). 
 “Monza-FSA Specifications” shall have the meaning set forth in Section 2(c). 
 “NRE” means non-recurring engineering. 
 “Order” shall have the meaning set forth in Section 8(a)(i). 
 “Pre-Paid Amount” shall have the meaning set forth in Section 5(a)(i). 
 “Product”
means Monza, Monza-2, and/or Monza-FSA, as applicable. 
 “Product Acceptance” shall have the meaning set forth in
Section 2(a). 
 “Product Acceptance Date” shall have the meaning set forth in Section 2(a).

 “Specifications” means either the Monza Specifications, Monza-2 Specifications or Monza-FSA Specifications. 

“Risk Wafers” shall have the meaning set forth in Section 3(a). 
 “Sample Testing Procedure” shall mean a process by which Impinj tests up to 200 die on a Monza-FSA wafer and extrapolates to determine
the number of good die on the entire wafer. A detailed definition of this process will be determined mutually at a later date. 
 “Testing” means those test procedures for Products as set forth in Exhibit B. 
 “Walmart” means
Wal-Mart Stores, Inc. 
  

	2.	Evaluation, Development and Product Specifications. 

 (a) Monza. 
 (i) Specifications. The Monza Specifications, including performance specifications,
current as of the Effective Date are set forth in Impinj’s documentation provided to Alien on or about May 18, 2005 (“Monza Specifications”), and attached hereto as Exhibit A. Monza shall perform in accordance with the
performance specifications included as part of the Monza Specifications. Impinj shall update the Monza Specifications from time to time as conditions warrant and to conform with the updates to the Gen2 Specification with the consent of 

  

 5 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Alien, which consent shall not be unreasonably withheld. When used in this Agreement, Monza Specifications refers to the most recent version agreed to by the
parties. 
 (ii) Product Acceptance. Impinj shall submit Monza to certify its compliance with the Gen2 Specification
according to procedures established by EPCglobal and, at its sole cost and expense, Impinj shall revise and resubmit Monza until such time as EPCglobal or one of its designated third party compliance laboratories certifies Monza as compliant with
the Gen2 Specification; provided however, that if after three (3) such submissions, Monza is not certified, the parties will discuss in good faith next steps to obtain certification for Monza, if obtainable, and Impinj shall not have further
obligation to submit Monza to EPCglobal. Any version of Monza that: (1) is certified by EPCglobal or one of its designated third party compliance laboratories as compliant with a Gen2 Specification; (2) implements a version of the Gen2
Specification that Walmart indicates it will accept; and (3) materially complies with the Monza Specifications, shall be deemed accepted hereunder (the “Product Acceptance”). The latter of the dates that: (1) a version of Monza
is certified as compliant with a Gen2 Specification in accordance with above; (2) Walmart first publicizes or otherwise indicates its intent to accept products compliant with such version of the Gen2 Specification; and (3) Testing for
Monza is completed, and Monza materially complies with the Monza Specifications, shall be the “Product Acceptance Date.” If, for any reason, Walmart publicizes or otherwise indicates its intent to no longer accept the version of the Gen2
Specification with which the Monza Specification is compliant, then (i) Impinj shall immediately notify Alien, (ii) Alien shall have the right to cancel any outstanding Orders in accordance with this Agreement, and thereafter
(iii) Alien shall have the right to terminate this Agreement. 
 (iii) Samples of Monza-Based Straps or Inlays.
Within eight (8) weeks of delivery of the first Risk Wafer (as described in Section 3(b)), Alien shall produce and deliver to Impinj at least one thousand (1,000) known good straps or inlays incorporating Monza die from such
Risk Wafer. Each party shall evaluate the performance of such straps or inlays within two (2) weeks of delivery to Impinj. The parties shall share the results of such performance evaluation. Such results shall be deemed Confidential Information
of both parties. Each party agrees not to distribute to any third party or otherwise allow any third party to sample any Alien-assembled strap or inlay incorporating any Monza die arising from the first Risk Wafer (as described in
Section 3(b)) without the prior written consent of the other party. 
 (b) Monza-2. Impinj may develop a cost-reduced
version of Monza (“Monza-2”) provided that Impinj shall have no obligation to develop, release or sell Monza-2. If Impinj decides to develop, release or sell Monza-2, the specifications for Monza-2 shall be as set forth by Impinj
(“Monza-2 Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience gained with Monza wafers. If it is evident that typical performance of
Monza is better than is reflected in the Specification, the acceptance specification for Monza-2 will be shifted toward more sensitivity, by mutual agreement of the parties. Provided that Alien is not in breach of this Agreement, Impinj will provide
Alien with early access and beta versions of Monza-2 and metal variants of Monza-2 no later than it provides access to other Impinj customers. 
  

 6 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Monza-FSA. Following receipt of the applicable NRE fees set forth herein, Impinj agrees to
use commercially reasonable efforts to develop a customized Monza product that is compatible with Alien’s patented “Fluidic Self Assembly” process (“Monza-FSA”); provided that Alien provides such information and
assistance as is reasonably requested by Impinj. Alien acknowledges and agrees that such development efforts may be unsuccessful and Impinj shall have no obligation to release or sell Monza-FSA. The specifications of the Monza-FSA (if and when
available) shall be as mutually agreed to by the parties in writing (“Monza-FSA Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience
gained with Monza wafers. If it is evident that typical performance of Monza is higher than is reflected in the Specification, the acceptance specification for Monza-FSA will be shifted toward more sensitivity, by mutual agreement of the parties.
Monza-FSA Specifications may include a test structure that will allow Impinj to use its standard test procedures to determine wafer yields on a sampling basis (i.e., wafers to include test structures built into reticles for Impinj to test prior to
sending to Alien). For those portions of the Monza-FSA that are Alien’s Intellectual Property as defined under Section 10(c) (“FSA Intellectual Property”), such FSA Intellectual Property shall be and remain Alien
Confidential Information. Impinj shall have no right to sell, license, transfer or otherwise distribute the FSA Intellectual Property. 
  

	3.	Risk Wafers. 

 (a) Definition. All orders by
Alien or deliveries by Impinj of Monza wafers shall be deemed “Risk Wafers” until Impinj provides written notice that it is releasing Monza into production. 
 (b) Initial Delivery of Risk Wafer. On or prior to June 30, 2005, Impinj shall deliver to Alien without charge or other expense one
(1) Risk Wafer along with one thousand (1,000) assembled Monza tags and one hundred (100) Monza die in waffle pack. 
 (c)
First Order and Delivery of Risk Wafers. On May 20, 2005, Alien issued a non-cancelable Order for [***] Risk Wafers (“Risk Wafer Order”). Impinj acknowledges receipt of the Risk Wafer Order. The schedule delivery date of
such Risk Wafers shall be twelve (12) weeks from May 20, 2005. For purposes of clarification, the single Risk Wafer delivered to Alien pursuant to Section 3(b) shall not be included within such [***] Risk Wafer Order. Except
for the restrictions of Section 2(a)(iii), nothing contained herein shall prevent Alien from selling or otherwise distributing straps, inlays, or labels built using the Risk Wafers purchased under this Section 3(c) to Alien’s
resellers and end customers. 
 (d) AS-IS Without Warranty. Alien acknowledges and agrees that all Risk Wafers are sold “AS
IS” without any warranty of any kind. 
  

	4.	Minimum Purchase Requirements. 

 (a) Total
Minimum Purchase Amount. During the term of this Agreement, subject to Impinj’s compliance with its material obligations and liabilities hereunder, Alien shall purchase a minimum of [***] units of Product (“Minimum Purchase
Amount”). Such minimum may 

  

 7 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
comprise any combination of units of Monza, Monza-2 and Monza-FSA, subject to Alien’s discretion and, in the case of Monza-2 and Monza-FSA, availability
from Impinj. Alien acknowledges that the Risk Wafer specified in Section 3(b) shall not be counted towards the Minimum Purchase Amount. Risk Wafers specified in Section 3(c) shall be counted towards the Minimum Purchase
Amount. In addition, the parties agree that the determination of the number of units of Product on a single wafer for purposes of accounting for the Minimum Purchase Amount shall be the number of KGD on that wafer. 
 (b) Timing of Minimum Purchase Amount. 
 (i) Subject to Section 4(d), Alien shall issue non-cancelable Orders for the Minimum Purchase Amount by [***] and receive delivery of the same by [***]. 
 (ii) Subject to Section 4(d), Alien shall issue non-cancelable Orders and receive delivery for: (1) at least [***] of
Product by [***]; and (2) at least an additional [***] by [***]. Alien acknowledges and agrees that it shall place such Orders prior to the applicable Lead Times. 
 (c) Order Increments. Alien acknowledges and agrees that Impinj delivers Monza and Monza-2 in whole wafer increments. Alien acknowledges and agrees that the yield of a particular wafer may vary and as such, the
number of KGD on each wafer may vary. As such, in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order up to an additional [***] units of Monza or Monza-2 Product. Alien acknowledges and agrees that Impinj delivers
Monza-FSA in whole lot increments, consisting of twenty-five (25) wafers. Alien acknowledges and agrees that the yield of a particular lot may vary. As such, in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order
up to an additional twenty-five (25) wafer lot of Monza-FSA. 
 (d) Timing of Product Acceptance. In the event that the Product
Acceptance Date does not occur by September 1, 2005, the delivery dates set forth in Section 4(b) shall be extended one day for each day that the Product Acceptance Date is after September 1, 2005. For purpose of illustration,
if the Product Acceptance Date occurs on September 21, 2005, each of the delivery dates set forth in Section 4(b) shall be extended by twenty (20) days. 
  

	5.	Payments. 

 (a) Prepayments. 
 (i) Amount. Subject to Section 5(a)(ii), Alien shall pay Impinj a non-refundable [***] (“Pre-Paid Amount”) as
a prepayment for certain amounts due under this Agreement. 
 (ii) Timing. Alien shall pay Impinj the Pre-Paid Amount
the later of (1) seven (7) days following the Product Acceptance Date and (2) September 1, 2005; provided however that in the event the Product Acceptance date does not occur by December 31, 2005 and Alien 

  

 8 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
terminates this Agreement pursuant to Section 13(b)(i), Alien shall have no obligation to pay the Pre-Paid Amount. 
 (iii) Allocation. 
 (1) NRE Fees for Development of Monza-FSA. The parties agree that the Pre-Paid Amount shall be used to fully satisfy the NRE fees due to Impinj for the development of Monza-FSA pursuant to
Section 6(e). 
 (2) Credit for Product Purchases In Excess of [***]. The parties agree that the amount of
the Pre-Paid Amount remaining after Alien has paid Impinj the applicable NRE fees due under Section 6(e) (i.e., [***] if the NRE fees are [***] or [***] if the NRE fees are [***]) (the “Credit Amount”) may be used as a
credit against purchases of production orders of (i) Monza or Monza-2 versions of the Product in excess of the [***] of production versions of Product ordered by Alien pursuant to this Agreement, and (ii) Monza-FSA versions of the Product
commencing on the initial production versions of Product ordered by Alien pursuant to this Agreement. The Credit Amount shall be credited against such purchases at a rate of [***]. The Credit Amount must be used by Alien within six (6) months
of the date Alien purchases its forty millionth unit of production Product. If Alien fails to fully use the Credit Amount by such date, Alien shall not be entitled to the benefit of any remaining amount of the Credit Amount. 
 (b) Payment Terms. Alien shall pay Impinj all invoiced amounts net thirty (30) days from the date of Alien’s receipt of each invoice.
All payments due under this Agreement shall be made in US dollars by check or bank wire transfer to an account designated by Impinj. Without prejudice to any other remedy, in the event any amount is not paid by Alien when due, following ten
(10) business days written notice by Impinj to Alien during such time Alien having the right to cure, Impinj may assess, and Alien agrees to pay, a late charge of the lesser of one and one quarter percent (1.25%) per month or the maximum
percentage allowed by law for each month or portion thereof that the amount is past due. 
 (c) Taxes. Amounts payable to Impinj under
this Agreement are payable in full to Impinj without deduction and are net of taxes (including any sales, use, excise, ad valorem, property, withholding, value added tax, or other tax and any income tax withheld at source), tariff, duty or
assessment levied or imposed by any government authority that may be applicable to the transactions contemplated by this Agreement based on delivery terms set forth in Section 8(b), exclusive of taxes based on Impinj’s net income
and any taxes (including those set forth above in this paragraph) prior to delivery to Alien. 
  

	6.	Fees and Prices. 

 (a) Risk Wafers. The price
of each Risk Wafer ordered by Alien pursuant to Section 3(c) shall be [***]. The total purchase price of the first order of Risk Wafers shall be [***]. Additional risk wafers ordered (excluding Section 6(c)) will be priced in accordance
with Section 6(b). 
  

 9 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (b) Prices of Product Purchased to Meet the Minimum Purchase Amount. 
 (i) Monza. For Monza Product that is purchased to meet the Minimum Purchase Amount, the unit price for each Monza KGD shall be
[***] subject to offset by the Credit Amount applicable to each unit. For purposes of clarification, Alien shall only be required to pay for each KGD on Monza wafers. As such, any non-KGD on any Monza wafer may not be used to satisfy any part of the
Minimum Purchase Amount. 
 (ii) Monza-2. For Monza-2 Product (if and when available) that is purchased to meet the
Minimum Purchase Amount, the unit price for each Monza-2 KGD shall be [***] multiplied by the ratio of the number of die on a Monza wafer over the number of die on a Monza-2 wafer (unless a lower unit price is mutually agreed by the parties in
writing) subject to offset by the Credit Amount applicable to each unit. For purposes of illustration, if the number of die on a Monza-2 wafer is [***] larger than the number of die on a Monza wafer, the unit price for each Monza-2 KGD shall be
[***]. For purposes of clarification, Alien shall only be required to pay for each KGD on Monza-2 wafers. As such, any non-KGD on any Monza-2 wafer may not be used to satisfy any part of the Minimum Purchase Amount. 
 (iii) Monza-FSA. For Monza-FSA Product (if and when available) that is purchased to meet the Minimum Purchase Amount, the unit
price for each Monza-FSA wafer shall be [***] (“MW Price”) subject to certain price adjustments as described below in this Section 6(b)(iii); provided, that Monza-FSA is available from Impinj in production quantities prior to [***].
Additionally, in the event Monza-FSA wafer yields are less than the Minimum FSA Yield, then the MW Price shall be decreased to reflect the actual percentage yield below the Minimum FSA Yield. Commencing with Impinj’s first shipment of
production versions of Monza-FSA, the Minimum FSA Yield shall be [***], and shall increase by [***] for each Monza-FSA lot accepted by Alien thereafter up to a maximum of [***]. For Monza-FSA wafers whose yield is lower than the Minimum FSA Yield,
Impinj will offer a price discount from the MW Price equal to the percentage difference between the actual yield of the wafer and the Minimum FSA Yield. For purposes of clarification, in the event a wafer from the third lot of Monza-FSA shipped by
Impinj has a yield of [***], then Alien will be entitled to a [***] discount from the MW Price for that wafer [***]. Monza-FSA wafer yields will be set by the Sample Testing Procedure. 
 (c) Prices of Product Purchased In Excess of the Minimum Purchase Amount. If Alien commits to purchase an annual volume of Products in excess of
fifty million units (in addition to the Minimum Purchase Amount) under the terms and conditions of this Agreement, Impinj agrees that the purchase prices for such Products shall be no higher than the prices set forth in Section 6(b).

 (d) [***]. During the term of this Agreement, Impinj agrees that if Impinj sells Products to a third party [***], taken as a whole,
that are [***], this Agreement and any outstanding Orders shall be deemed [***]. Impinj warrants that the terms and conditions reflected herein [***]. 
 (e) NRE Fees for Development of Monza-FSA. Alien shall pay Impinj [***] as NRE fees in consideration of Impinj’s development efforts set forth in 

  

 10 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Section 2(c). The NRE fees may be increased to [***] if mutually agreed to in writing by the parties. For purposes of clarification, the NRE fee
in this Section 6(e) is the same (and not in addition to) the NRE referenced elsewhere in this Agreement. 
  

	7.	Forecasts; Lead Times; Delivery Requirements. 

 (a)
Forecasts. Within the first ten (10) days of the beginning of each calendar month, Alien shall provide Impinj with a written twelve (12) month rolling forecast, updated monthly setting forth Alien’s estimated monthly
requirements for Products. The first [***] of such forecast shall be binding (subject to rescheduling, cancellation and other provisions hereof), and Alien shall issue non-cancelable Orders within the applicable Lead Times to cover such period. The
remaining [***] of such forecast shall be non-binding; provided, however, Alien may, in its discretion, issue non-cancelable Orders to cover such period. 
 (b) Lead Times. Alien acknowledges that the lead times for the Products in production quantities (“Lead Times”) are currently [***] for Monza and expected to be [***] for Monza-2 (if and when
available) and Monza-FSA (if and when available). Lead Times are associated with wafer processing alone and do not contemplate back end processing functions such as bumping, thinning, scribing, etc. Impinj shall provide Alien prompt written notice
if the Lead Times change. 
 (c) Delivery Requirements. 
 (i) Order Increments. Alien acknowledges and agrees that delivery of all Products shall be in accordance with Section 4(c).

 (ii) Yield of Product Wafers. Impinj acknowledges and agrees that it will not ship Monza or Monza-2 wafers to Alien
that have a yield less than [***], except as may be agreed upon by the parties in writing with price reductions as set forth below. Impinj acknowledges and agrees that it will not ship Monza-FSA wafers to Alien that have a yield less than [***],
except as may be agreed upon by the parties in writing with appropriate price reductions as set forth in Section 6(b)(iii), such yield to be determined in a manner to be mutually agreed to by the parties. For Monza-FSA, if Impinj fails to
deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer those wafers for sale to Alien with appropriate price reductions as set forth in
Section 6(b)(iii). For Monza and Monza-2, if Impinj fails to deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer a price discount equal to
the percentage difference between the actual yield of the wafer and [***]. For example, if Impinj sells a wafer to Alien with [***] yield, Alien will be entitled to a [***] discount on the KGD price which has been set in accordance with
Section 6(b). 
 (iii) Form of Monza and Monza-2 Wafers. The production versions of Monza and Monza-2 wafers
delivered to Alien shall not be bumped, thinned or otherwise post-processed. Such wafers shall be initialized (i.e., Impinj will program a valid electronic product 

  

 11 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
code into the appropriate 96-bit memory field of Monza or Monza-2 die) and provided with wafer maps that identify the KGD. 
 (iv) Form of Monza-FSA Wafers. The production versions of Monza-FSA wafers delivered to Alien shall pass standard process control
monitor (“PCM”) tests at Impinj’s foundry and such additional testing and initialization processes as agreed by the parties in the course of developing Monza-FSA. Impinj shall, at a minimum, sample test such wafers but Impinj shall
not be required to bump, thin or otherwise post-process such wafers. Any additional testing or initialization procedures shall be as mutually agreed in writing during the development of Monza-FSA. 
 (v) Performance of Monza and Monza-2 wafers. The wafers that Impinj provides to Alien will have no less sensitivity than those it
sells to others or uses for its own production. 
  

	8.	Order Process; Shipping and Title; Acceptance of Shipments. 

 (a) Order Process. 
 (i) All purchases and sales between Impinj and Alien hereunder shall be initiated by
Alien’s issuance of written purchase orders (“Orders”) to Impinj. All Orders shall include the following: (1) purchase order number; (2) Product number, description and price (by line item); (3) billing address;
(4) shipping address; (5) requested shipment date; (6) authorized signature; and (7) such other information as Impinj may reasonably request. 
 (ii) Impinj agrees to acknowledge Alien’s Orders in writing, or electronically where an electronic data interchange procedure has
been agreed to by the parties, within five (5) working days of receipt. If Impinj is unable to accept any purchase order, Impinj shall give Alien a written explanation. Impinj may not reject or amend any Order that conforms to the terms and
conditions of this Agreement, unless such Order is required to be reduced by allocation under Section 8(b)(iii). 
 (iii)
This Agreement shall govern all orders of Products by Alien. No terms on Orders, invoices or like documents by either party shall serve to alter or add to the terms of this Agreement unless agreed to and signed by both parties in writing.

 (iv) Without Impinj’s prior written consent and except as provided expressly herein, Alien shall have no right to make
any modifications or additions to any Order that has been accepted by Impinj. 
 (v) No later than sixty (60) days prior
to the shipping date, Alien may reschedule any Order for delivery up to thirty (30) days after the original shipping date without charge or penalty. Less than sixty (60) days prior to the shipping date, Alien may only reschedule an Order
with the consent of Impinj. 
  

 12 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (vi) Alien may cancel an Order at any time upon written notice to Impinj; provided,
however, that Alien pays to Impinj the amounts described in this section. Alien will be liable to pay to Impinj any penalties or cancellation fees charged to Impinj by Impinj’s suppliers as a direct consequence of Alien’s cancellation of
the Purchase Order, less any amounts charged for materials that are refundable (collectively, the “Cancellation Fee”). Notwithstanding the foregoing, unless expressly agreed to the contrary in writing by the parties at the time that the
Order is accepted, the Cancellation Fee may not exceed the total invoice value of the Order. Impinj will use its commercially reasonable efforts to minimize, and will perform any commercially reasonable acts necessary to mitigate, any applicable
Cancellation Fees. Upon receipt of notice of cancellation, Impinj will notify Alien within ten (10) business days of the precise amount of the Cancellation Fee, and Alien will have the right to either (1) withdraw its notice of
cancellation and require Impinj to continue to fulfill the Purchase Order; or (2) confirm the cancellation and pay the Cancellation Fee. Failure by Alien to notify Impinj of withdrawal of its notice of cancellation within five (5) business
days after receiving from Impinj the precise amount of the Cancellation Fee will be deemed confirmation of cancellation by Alien. Upon confirmation of any cancellation and receipt from Impinj of an invoice for a Cancellation Fee, Alien will pay the
full Cancellation Fee to Impinj in accordance with the terms of Section 5(b). Notwithstanding the foregoing, Alien may cancel any Order without the obligation to pay any cancellation fee if Impinj fails to deliver Products within thirty
(30) days after the scheduled shipping date. Except as set forth in Section 8(b)(ii), Orders cancelled prior to shipment will not apply towards the Minimum Purchase Amount. 
 (vii) In the event of a suspected Epidemic Failure, Alien shall promptly notify Impinj, and shall provide the following information, if
known and as may then exist: a description of the defect, and the suspected lot numbers, serial numbers or other identifiers, and delivery dates of the defective Products. Alien shall also make available to Impinj samples of the defective Products
for testing and analysis. Within five (5) business days of receipt of notice from Alien, Impinj shall provide its preliminary findings regarding the cause of the failures. Thereafter, Impinj shall promptly provide the results of its root cause
corrective analysis, its proposed plan for the identification of and the repair or replacement of the affected Products, and such other appropriate or desirable information as Alien may reasonably request. The parties shall also cooperate to
expeditiously devise and implement a corrective action program which identifies the defective units for repair or replacement, and which minimizes disruption to Alien’s customers. 
 (b) Shipping and Title. Delivery is FOB Impinj’s facilities (currently in Orange County, CA) (the “Delivery Point”). Title
to, and risk of loss of, the Products shall pass to Alien upon delivery by Impinj to Alien’s designated carrier at the Delivery Point. 
 (i) Impinj will handle and pack all Products so as to protect the Products from loss or damage in transit, in a manner consistent with standard commercial practice and approved by Alien. Subject to Sections 8(b)(ii)
and 8(b)(iii) below, Impinj will endeavor to ship the Impinj Products on or before the shipping date. 
 (ii) In the event of
any delays that cause the shipment to ship four (4) days or more after the scheduled shipping date, and without limiting Alien’s other rights and remedies 

  

 13 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
hereunder, Impinj shall immediately notify Alien of such delay and shall use its commercially reasonable efforts to remedy such delay immediately. In the
event of such delay, Alien may cancel the Order; provided however that the KGD for such shipment shall apply to the Minimum Purchase Amount (or in the event the KGD for such shipment is not known, then the amount attributable to the Minimum Purchase
Amount shall be an amount equal to the average KGD determined over the most recent wafer lot received by Alien). If not cancelled by Alien, Impinj shall use expedited means to ship the Products, at its own expense, to minimize any further delay.

 (iii) If a supplier to Impinj has inadequate capacity to timely fulfill both Alien’s Orders for Products and
Impinj’s other requirements for Impinj Products (including Impinj’s own use of Products), then, without limiting any of Alien’s other rights and remedies, Impinj will allocate the available capacity in a manner that proportionally
reflects Alien’s orders for Products during the previous ninety (90) days. For example, if during the previous ninety days, Alien accounted for sixty percent (60%) of the total production of Impinj Products, then in the event of
inadequate supplier capacity, Impinj will allocate sixty percent (60%) of the available capacity to meet Alien’s requirements for Products. Impinj will work with Alien in good faith to resolve any customer difficulties that may arise
during a period of inadequate capacity, and the parties may mutually agree upon an allocation formula that differs from that set forth above in order to meet urgent Alien requirements. 
 (iv) Impinj will obtain the written consent of Alien prior to implementing any changes to the form, fit, or function of the Products,
which consent may be withheld by Alien in its sole discretion. If Alien elects to withhold such consent, Impinj may implement such changes, but will continue to make available the unchanged variants of the Products to Alien. 
 (c) Acceptance of Shipments. Alien shall give notice to Impinj (and the carrier where appropriate) of discrepancies between Product ordered and
delivered, and of damage to the Product within eleven (11) business days of delivery to the Delivery Point. Lacking such notice, Alien shall be deemed to have received the Product as invoiced, provided however that receipt shall not mean
Acceptance. Alien shall accept (“Acceptance” or “Accepted”) or reject Products included in each shipment within sixty (60) days from delivery. If Alien fails to notify Impinj in writing of its rejection and the reasons
thereof within such time period, Alien will be deemed to have Accepted such shipment. Product may be returned to Impinj only after prior notification and subsequent authorization upon receipt of a return material authorization number issued by
Impinj, provided however that the Acceptance period shall be extended on a day by day basis to the extent Impinj fails to timely provide return authorization. No credit allowances for defective Product will be made or replacements therefore shipped
until Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting, assembly process, post-processing of any Product after delivery (including without limitation
Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper testing that was not authorized or directed by Impinj. Acceptance of Product shall not modify or
otherwise change the applicable Product warranties, and Acceptance shall not constitute a waiver of such Product warranties. 
  

 14 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	9.	Limited Product Warranty. 

 (a) Limited Product
Warranty. Following release of Products into production, Impinj warrants as follows: 
 (i) that such Products supplied to Alien hereunder
shall materially conform to the applicable Specifications of such Product and shall be free from defects in materials and workmanship, (the “Limited Product Warranty”) during the Limited Warranty Period. For purposes of
clarification, the foregoing Limited Product Warranty shall not be applied to any Risk Wafers, engineering wafers or any Products labeled as beta or evaluation versions; 
 (ii) that Products will be new, and free and clear of all liens, encumbrances, security interests, and other claims; 
 (iii) that to Impinj’s knowledge, the Products will not infringe or misappropriate any Intellectual Property Rights of any third party; and 
 (iv) that Impinj has the right and power to enter into this Agreement and grant to Alien the rights set forth herein. 
 (b) Alien’s sole remedy in relation to the warranties under Section 9(a) shall be that: Impinj shall replace, refund or credit, at Impinj’s sole discretion, Alien’s account for any such
Products which are returned by Alien during the warranty period set forth above, (provided that for the last Order under this Agreement, if such Products cannot be replaced, Impinj shall refund amounts to Alien) provided that: 
 (i) Impinj is promptly notified in writing upon discovery by Alien that such Products failed to conform to this Agreement with an explanation of any
alleged deficiencies, 
 (ii) if: 
 (x) still in Alien’s custody then Impinj may require that Alien return such Product, at Impinj’s request; or 
 (y) not
still in Alien’s custody but provided that Alien has agreed to repair, replace or provide a refund/credit to Alien’s customer, then Alien shall have no obligation to return Product outside its custody, and 
 (iii) Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting,
assembly process, post-processing of any Product after delivery (including without limitation Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper
testing, that was not otherwise approved or directed by Impinj. Impinj shall be responsible for all costs associated with shipping replacement Products to Alien (Duty Delivery Paid) Alien’s designated location. 
  

 15 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) DISCLAIMER. THE LIMITED WARRANTIES SET FORTH IN THIS SECTION 9 ARE IN LIEU OF
ALL CONDITIONS OR WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED CONDITION OR WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND OF ANY OTHER WARRANTY OBLIGATION ON THE PART OF IMPINJ.

  

	10.	Restrictions; Intellectual Property Rights. 

 (a)
Restrictions. Alien agrees not to: (i) sell or otherwise distribute to any third party any Product in wafer, die (except as packaged in a strap, inlay, tag, label or similar) or raw silicon form; (ii) use any Monza or Monza-2 die
that is not marked as KGD (and Alien agrees to destroy all such non-KGD die); (iii) reverse engineer or otherwise attempt to gain access to logic, structure or design of any Product; (iv) modify or create derivative works of any Product
(except as part of Alien’s FSA process); (v) use any Product in any products or systems for which errors, bugs or malfunctions could cause personal injury or death, property or environmental damage, including without limitation, medical
life support systems (which for the purposes of this Agreement shall exclude pharmaceutical or hospital patient tracking applications), on-line control of aircraft, air traffic, air navigation or aircraft communications or in the design or operation
of any nuclear facility; or (vi) cause or grant permission to any third party to do any of the foregoing. 
 (b) Monza and
Monza-2. Impinj owns and shall retain all Intellectual Property Rights in and to Monza and Monza-2. Improvements, modifications or enhancements to Intellectual Property shall be as set forth in the Intellectual Property Agreement between the
parties, dated May 5, 2005. 
 (c) Third party Infringement. Impinj shall notify Alien in the event Impinj receives or becomes
aware of any notice of any claim, suit or proceeding alleging that Monza infringes any third party Intellectual Property Rights. Alien shall notify Impinj in the event Alien receives or becomes aware of any notice of any claim, suit or proceeding
alleging that FSA Intellectual Property or Alien’s technology used to assemble Monza chips infringes any third party Intellectual Property Rights. 
 (d) Monza-FSA. Ownership of and licenses to Intellectual Property and Intellectual Property Rights shall be as set forth in the Intellectual Property Agreement between the parties, dated May 5, 2005.

 (e) Reservation of Rights. Each party reserves all rights not expressly granted in this Agreement, and no licenses are granted by
either party to the other party under this Agreement, whether by implication, estoppel or otherwise, except as expressly set forth herein. 
 (f) Covenant of Further Assurances. Each party shall, without demanding any further consideration therefor, at the request and expense of the requesting party take all such actions and execute all such documents as reasonably
requested by the other party, in order to effect the intent of this Section 10. 
  

 16 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	11.	Confidentiality; Press Releases. 

 (a) Duty to
Maintain Confidentiality. Each party agrees to accept Confidential Information from the other party solely for use in connection with performance of its obligations and exercise of its rights granted under this Agreement and that for a period of
five (5) years from the date of disclosure it will hold in strict confidence and not disclose, publish, or disseminate such Confidential Information to anyone other than those of its employees and subcontractors with a need to know and who have
executed appropriate confidentiality agreements, nor use Confidential Information for its own or any third party’s benefit, without the prior written approval of an authorized representative of the originating party. The receiving party will
protect Confidential Information of the disclosing party from disclosure, publication, dissemination and unauthorized use with the same degree of care the receiving party uses to protect its own confidential and proprietary information of similar
nature, but in no event less than a reasonable degree of care. Notwithstanding the foregoing, and subject to the restrictions in Section 2(a)(iii), in no event shall Alien be prevented from distributing information about its products that
include Products purchased hereunder provided that such information does not include Confidential Information of Impinj. 
 (b)
Exceptions. The receiving party may disclose Confidential Information if required by operation of law or any tribunal of competent jurisdiction, provided that it will take reasonable steps to first give the originating party sufficient prior
notice to contest the order to disclose, and must cooperate with the originating party in any efforts by the originating party to obtain a protective order or other confidential treatment. The parties shall have the right to disclose the terms of
this Agreement to attorneys, government agencies, financial advisors and potential investors and acquirers (of the party or the party’s relevant foundry, division, or product line), subject to reasonable confidentiality provisions which are no
less restrictive than those provided for herein. 
 (c) Injunctive Relief. The parties acknowledge that any breach or threatened
breach of the obligations of confidentiality contained in this Section 11 may cause substantial harm to the non-breaching party that may not be reasonably or adequately compensated with monetary damages. Accordingly, in addition to any
other available remedies, the parties recognize each party’s right to seek injunctive relief in connection with such breach or threatened breach. 
 (d) Press Releases. The parties agree to issue two (2) joint press releases upon the completion of the milestones as follows: (1) one press release announcing the sampling of Alien-assembled straps or
inlays incorporating Monza die (as set forth in Section 2(a)(iii)) upon the commencement of such sampling; and (2) one press release announcing the commencement of volume production of Monza upon Alien’s order of the first
production quantities of Monza. Each such press release shall indicate that the silicon is produced by Impinj and the straps and inlays are produced by Alien. 
  

	12.	Indemnification. 

 (a) By Impinj. Impinj
shall indemnify, defend and hold harmless Alien from and against any and all third party claims, actions, losses, liabilities, damages, costs and expenses (including but 

  

 17 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
not limited to reasonable attorneys’ fees and costs) to the extent based on a claim that any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA,
only to the extent that Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights) supplied by Impinj to Alien hereunder constitutes infringement or misappropriation of any third party Intellectual Property
Rights and Alien compliance with Impinj’s specifications. (collectively a “Product IP Claim”). Impinj shall not be obligated to defend or be liable for costs and damages if: (i) the infringement arises out of compliance
with Alien’s specifications or instructions or the FSA Intellectual Property; (ii) the infringement arises from a combination with, an addition to, or a modification of the Products after delivery by Impinj; or (iii) the infringement
arises from use of the Products, or any part thereof, in the practice of a process. Impinj’s obligations hereunder shall not apply to any infringement occurring after (i) Impinj has received notice of such suit or proceeding or other
communication alleging the infringement and (ii) Impinj provides such notice to Alien, unless Impinj gives written permission for such continuing infringement. In the event Impinj provides Alien with such notice, and the infringement does not
arise under conditions described in Section 12(b), Alien shall have the right to terminate this Agreement and any Orders without cost or penalty. 
 If
any infringement by Impinj is alleged prior to completion of delivery of the Products under this Agreement, Impinj may decline to make further shipments without being in breach of this Agreement. 
 Without limiting Impinj’s obligations above, if any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA, only to the extent that Monza or Monza-2, as
applicable, alone would have infringed the same Intellectual Property Rights without the FSA Intellectual Property) supplied by Impinj to Alien hereunder shall be held to directly infringe Intellectual Property Rights, and Alien shall be enjoined
from using the same, Impinj shall (or if Impinj reasonably believes that such an injunction may be issued, Impinj may) use reasonable efforts, at its option and at its expense, (i) to procure for Alien the right to use such products free of any
liability for infringement, or (ii) to replace such products with a noninfringing substitute otherwise complying substantially with all requirements of this Agreement, or if the aforesaid enjoinment is confirmed and neither of the actions under
(i) or (ii) above are available on commercially reasonable terms, to (iii) accept return of such products and refund the purchase price of such returned products. 
 (b) By Alien. Alien shall indemnify, defend and hold harmless Impinj from and against any and all claims, actions, losses, liabilities, damages,
costs and expenses (including but not limited to reasonable attorneys’ fees and costs, but excluding any Product IP Claim) to the extent based on a claim that (i) any strap or inlay product from Alien incorporating any Product (but not if
Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights without the strap or inlay product from Alien); (ii) Impinj’s compliance with Alien’s specifications; (iii) any combination with,
addition to, or modification of the Products after delivery by Impinj to Alien; or (iv) the FSA Intellectual Property; infringes or misappropriates any third party Intellectual Property Rights. 
 (c) Procedures. All indemnification obligations under this section shall be subject to the following requirements: (i) the indemnified party
shall provide the indemnifying party with 

  

 18 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
prompt written notice of any claim; (ii) the indemnified party shall permit the indemnifying party to assume and solely control the defense or
settlement of any claim (provided, that neither party shall enter into any settlement providing for any restriction on the other party without the other party’s prior written consent, such consent not to be unreasonably withheld);
(iii) the indemnified party shall provide proper and full information and all reasonable assistance to defend or settle any such claim, at the indemnifying party’s request and expense; and (iv) the indemnified party shall not have
compromised or settled any such claim without the indemnifying party’s prior written consent. In addition, the indemnifying party shall not be responsible for any costs, expenses, compromises, or settlements incurred or made by the indemnified
party without the indemnifying party’s prior written consent, and the indemnified party may, at its own expense, participate in its defense of any claim. 
 (d) Sole Remedy. THE FOREGOING PROVISIONS OF THIS SECTION 12 STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF EACH PARTY AND THE EXCLUSIVE REMEDY OF THE OTHER PARTY, WITH RESPECT TO ANY ALLEGED OR
ACTUAL INFRINGEMENT OF PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS OR OTHER INTELLECTUAL PROPERTY RIGHTS BY THE PRODUCTS. 
  

	13.	Term and Termination. 

 (a) Term. The term of
this Agreement shall commence on the Effective Date and expire six (6) months after the delivery of the fifty millionth Product (excluding Risk Wafers delivered pursuant to Sections 3(b) and 3(c)), unless earlier terminated as
provided herein. 
 (b) Termination. 
 (i) Delay of Product Acceptance. In the event that the Product Acceptance Date does not occur by December 31, 2005, this Agreement shall automatically terminate upon such date unless prior to such date the
parties agree (via written notice sent to the individuals specified in Section 15(g)) to extend the date by which the Product Acceptance must occur. If the parties so agree and the Product Acceptance does not occur by such extended date,
this Agreement shall automatically terminate on such extended date unless the parties otherwise agree to subsequently re-extend the date by which the Product Acceptance must occur. If this Agreement is terminated pursuant to this
Section 13(b)(i), Alien shall have no obligation to pay Impinj the Pre-Paid Amount or purchase the Minimum Purchase Amount. 
 (ii) For Cause. Either party may terminate this Agreement upon written notice in the event the other party materially breaches this Agreement and fails to cure such breach within thirty (30) days after the
date of written notice thereof by such party. 
 (iii) For Insolvency. Either party may terminate this Agreement by
written notice in the event: (1) the other party voluntarily enters into proceedings in bankruptcy or insolvency; (2) the other party makes an assignment for the benefit of creditors; (3) a petition is filed against the other party
under a bankruptcy law, a corporate reorganization law, or any other law for relief of debtors or similar law analogous in purpose or effect, which petition is not dismissed within one hundred and twenty (120) days of filing thereof; or
(4) the other party 

  

 19 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
enters into liquidation or dissolution proceedings or a receiver is appointed with respect to any assets of the other party, which appointment is not vacated
within one hundred and twenty (120) days. 
 (c) Effect of Termination. The following provisions shall survive any termination or
expiration of this Agreement: Sections 1, 4 (except for termination by Alien pursuant to Section 13(b)(i)), 5 (except for termination by Alien pursuant to Section 13(b)(i)), 9, 10,
11, 12, 13(c), 14 and 15. Nothing contained herein shall limit any other remedies that either party may have for the default of the other party under this Agreement nor relieve either party of any of its
obligations incurred prior to any expiration or termination of this Agreement. 
 (d) No Liability for Termination. Neither party
shall incur any liability or compensation obligation whatsoever for any damage (including and without limitation damage to or loss of goodwill or investment), loss or expenses of any kind suffered or incurred by the other party arising from or
relating to any termination of this Agreement pursuant to the terms hereof, whether or not such party is aware of any such loss or expenses. Termination is not the sole remedy and except as otherwise provided herein, all other remedies remain
available to each party. 
  

	14.	Limitation of Liability. 

 (a) EXCEPT FOR ANY BREACH
OF OR LIABILITY ARISING UNDER SECTIONS 10, OR 11, NEITHER PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHETHER SUCH DAMAGES ARE ALLEGED AS A RESULT OF TORTIOUS CONDUCT OR BREACH OF CONTRACT OR OTHERWISE, EVEN
IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. SUCH EXCLUDED DAMAGES SHALL INCLUDE BUT SHALL NOT BE LIMITED TO COST OF REMOVAL AND REINSTALLATION OF GOODS, LOSS OF GOODWILL, LOSS OF PROFITS, LOSS OF USE OF DATA, INTERRUPTION OF
BUSINESS OR OTHER ECONOMIC LOSS. REMEDIES PROVIDED HEREIN ARE INTENDED TO BE EXCLUSIVE (IN LIEU OF ANY OTHER REMEDY WHICH WOULD OTHERWISE HAVE BEEN AVAILABLE TO THE PARTIES AT LAW OR IN EQUITY). 
 (b) EXCEPT FOR ANY BREACH OF OR LIABILITY ARISING UNDER SECTIONS 4, 5(a), 10 OR 11, NEITHER PARTY’S TOTAL LIABILITY ARISING OUT OF OR
UNDER THIS AGREEMENT OR FOR BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED ONE AND ONE QUARTER (1.25x) THE TOTAL AMOUNTS PAID OR PAYABLE TO
IMPINJ HEREUNDER. 
 (c) EACH PARTY’S TOTAL LIABILITY ARISING OUT OF OR UNDER SECTION 4 OR FOR BREACH OF
SECTION 4, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED THREE MILLION EIGHT HUNDRED THOUSAND DOLLARS ($3,800,000) . EACH PARTY’S TOTAL LIABILITY
ARISING OUT OF OR UNDER SECTION 5(a) OR FOR BREACH OF SECTION 5(a), WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION 

  

 20 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED FIVE HUNDRED THOUSAND DOLLARS ($500,000). 
  

	15.	General. 

 (a) Governing Law; Venue. This
Agreement shall be governed by and construed under the laws of the State of California without regard to conflict of laws principles. The parties consent to the exclusive jurisdiction of, and venue in either Orange County, California, or Santa Clara
County, California, for any dispute arising out of or related to this Agreement. 
 (b) Assignment. Neither party shall transfer,
assign or delegate this Agreement or any rights or obligations hereunder, in whole or in part, whether voluntarily, by operation of law or otherwise, without the prior written consent of the other party, which consent shall not be unreasonably
withheld. Any purported transfer, assignment or delegation without such prior written consent will be null and void and of no force or effect. Notwithstanding the foregoing, each party shall have the right to assign this Agreement to any successor
to substantially all its business or assets to which this Agreement relates, whether by merger, sale of assets, sale of stock, reorganization or otherwise. Subject to the foregoing, this Agreement inures to the benefit of permitted successors and
assigns of each party. 
 (c) Waivers; Modification. No failure or delay (in whole or in part) by either party in exercising any
right, power, or remedy under this Agreement shall operate as a waiver of any such right, power, or remedy. No waiver or modification of any provision of this Agreement shall be effective unless in writing and signed by both parties. Any waiver by
either party of any provision of this Agreement shall not be construed as a waiver of any other provision or of such provision on any other occasion. 
 (d) Entire Agreement. Exhibits A and B are incorporated herein by this reference. This Agreement (including the Exhibits hereto) constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter hereof and supersedes any and all other agreements, written or oral, that the parties heretofore may have had with respect to the subject matter herein, including without limitation the term sheet signed by the
parties on May 20, 2005. 
 (e) Export. Each party agrees to fully comply with all applicable United States and foreign laws and
regulations with respect to the export, re-export, diversion or transfer of any products, technology, and information related to or exchanged under this Agreement, including without limitation the Export Administration Regulations issued by the
Department of Commerce, the International Trade Administration, and the Bureau of Export Administration, and the International Traffic in Arms Regulations (ITAR), including without limitation obtaining any necessary consents and requesting or filing
any documents. 
 (f) Severability. In the event any provision of this Agreement (or portion thereof, including the Exhibits hereto)
is determined by a court of competent jurisdiction to be invalid, illegal, or otherwise unenforceable, such provision shall be deemed to have been deleted from 

  

 21 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
this Agreement, while the remainder of this Agreement shall remain in full force and effect according to its terms. 
 (g) Notices. All notices permitted or required under this Agreement shall be in writing and shall be delivered in person, or by overnight delivery
service or by first class, registered or certified mail, postage prepaid, to the address of the party specified below or such other address as either party may specify in writing. Such notice shall be deemed to have been given upon delivery.

  

			
	 If to Impinj:
	  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Vinay Gokhale

	
	 With a required copy to:

		
		  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Legal Department

		
	 If to Alien:
	  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Thomas M.
Pounds

	
	With a required copy to:
		
		  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Legal
Department

 (h) Independent Contractors. The parties are independent contractors, and nothing in this
Agreement is intended to create any agency, partnership or joint venture relationship between them. 
 (i) Headings. The section
headings contained in this Agreement are included for convenience only, and shall not limit or otherwise affect the terms of this Agreement. 
 (j) Counterparts. This Agreement may be executed in any number of counterparts, and each executed counterpart shall have the same force and effect as an original instrument. 
 (k) Force Majeure. Neither party shall be responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its
reasonable control (other than payment of money), including but not limited to Acts of God, government actions, war, civil 

  

 22 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
disturbance, insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by suppliers or subcontractors, transportation difficulties,
shortage of energy, raw materials or equipment, or the other party’s fault or negligence. In the event of any such delay the date of delivery shall, at the request of such party, be deferred for a period equal to the time lost by reason of the
delay. 
 [Signature Page Follows] 
  

 23 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
Effective Date. 
  

									
	 Impinj:
	 		 	 Alien:

			
	 Impinj, Inc.
	 		 	 Alien Technology Corporation

					
	 By:
	 	 /s/ William T. Colleran
	 		 	 By:
	 	 /s/ John Payne

					
	 Name:
	 	 William T. Colleran
	 		 	 Name:
	 	 John Payne

					
	 Title:
	 	 President
	 		 	 Title:
	 	 Chief Operating Officer

  

 24 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit A 
 Monza Specifications 
 [***] 
  

 25 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing Procedures 
  

 26 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing 
 This exhibit describes the test procedures currently employed by Impinj on Monza Products. This test
procedure can be modified with the mutual agreement of the parties. The Impinj patented Monza test procedure uses dedicated hardware and software to test each wafer with minimal test time and maximal coverage relative to a conventional approach. The
test procedure requires dedicated circuits placed in the scribe lanes (area that is consumed when die sawing is performed) that enable a bypass port that gives parallel access to all die in the reticle; this port is referred to as the Reticle Test
Interface (“RTI”), and consists of a die site with [***]. This circuit interfaces with an array of Die Test Interfaces (“DTI”), one for each chip in the reticle and adjacent to the chip it tests. A bus structure with redundant
elements for fault tolerance connects the single RTI with the many DTIs. 
 In a conventional wafer probe test, each die is independent and is tested via its
primary I/O ports. If applied to RFID projects, with tens of thousands of die per wafer, conventional wafer probe tests effectively have a single serial interface that operates at UHF frequencies. This leads to poor test coverage, very long test
times, and unforgiving hardware fixtures. 
 In contrast, the Impinj approach provides full wafer-probe testing at that is very cost effective, and at a high
level of coverage. Monza wafers have nearly [***] yieldable die sites (gross die per wafer, or GDPW), and after DTI testing, typically [***] are identified as good die (net die per wafer, or NDPW). This shows a raw yield of about [***], which is
slightly higher than the prediction of the fab yield model at [***], consistent with a robust design. DTI testing does not enable 100% fault detection, however, and our models for DPPM reduction predict a residual test escape rate of [***], or
[***]. Hence, outgoing quality levels rise to [***], and become the practical meaning of “known good die”. 
 For reference, a series of [***]
tests comprising digital functionality over the Gen2 command set, key analog parameters, and read+write pattern testing of the NVM, is performed on the wafer. All circuit blocks are tested with the exception of the rectifiers and parts of the modem,
since their operation depends on a microwave signal. This constitutes the majority of the residual [***] loss. This remaining factor can be dealt with by a minimal, and very fast, RF test after inlay assembly, which is needed in any event to
identify assembly losses. Note that the net yield of inlays or straps rises from an estimated [***] to [***] (for an assumed [***] assembly yield), or a factor of [***] reduction in scrap rates, as a result of this capability. 
  

 27 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]